

Adenovirus small E1A directs activation of *Alu* transcription at YAP/TEAD- and AP-1-bound enhancers through interactions with the EP400 chromatin remodeler

Simona Cantarella^{1,†}, Marco Vezzoli^{1,†}, Davide Carnevali¹, Marco Morselli¹, Nathan R. Zemke², Barbara Montanini¹, Coralie F. Daussy³, Harald Wodrich³, Martin Teichmann⁴, Matteo Pellegrini⁵, Arnold J. Berk², Giorgio Dieci^{1,*} and Roberto Ferrari^{1,*}

¹Department of Chemistry, Life Sciences and Environmental Sustainability, University of Parma, 43124 Parma, Italy

²Molecular Biology Institute, University of California at Los Angeles, Los Angeles, CA 90095, USA

³Bordeaux University, CNRS UMR 5234, Fundamental Microbiology and Pathogenicity, Bordeaux, France

⁴Bordeaux University, Inserm U 1312, Bordeaux Institute of Oncology, 33076 Bordeaux, France

⁵Department of Molecular Cellular and Developmental Biology, University of California Los Angeles, Los Angeles, CA 90095, USA

*To whom correspondence may be addressed. Tel: +39 0521 905649; Email: giorgio.dieci@unipr.it

Correspondence may also be addressed to Roberto Ferrari. Tel: +39 0521 905646; Email: roberto.ferrari1@unipr.it

[†]The first two authors should be regarded as Joint First Authors.

Present addresses:

Simona Cantarella, Research Group RNA-protein complexes and Cell Proliferation, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.


Nathan R. Zemke, Department of Cellular and Molecular Medicine, University of California, San Diego School of Medicine, La Jolla, CA, USA.

Coralie F. Daussy, University of Montpellier, CNRS UMR 9004, Institut de Recherche en Infectiologie de Montpellier (IRIM), Montpellier, France.

Abstract

Alu retrotransposons, which form the largest family of mobile DNA elements in the human genome, have recently come to attention as a potential source of regulatory novelties, most notably by participating in enhancer function. Even though *Alu* transcription by RNA polymerase III is subjected to tight epigenetic silencing, their expression has long been known to increase in response to various types of stress, including viral infection. Here we show that, in primary human fibroblasts, adenovirus small e1a triggered derepression of hundreds of individual *Alus* by promoting TFIIIB recruitment by *Alu*-bound TFIIIC. Epigenome profiling revealed an e1a-induced decrease of H3K27 acetylation and increase of H3K4 monomethylation at derepressed *Alus*, making them resemble poised enhancers. The enhancer nature of e1a-targeted *Alus* was confirmed by the enrichment, in their upstream regions, of the EP300/CBP acetyltransferase, EP400 chromatin remodeler and YAP1 and FOS transcription factors. The physical interaction of e1a with EP400 was critical for *Alu* derepression, which was abrogated upon EP400 ablation. Our data suggest that e1a targets a subset of enhancer *Alus* whose transcriptional activation, which requires EP400 and is mediated by the e1a-EP400 interaction, may participate in the manipulation of enhancer activity by adenoviruses.

Graphical abstract



Received: July 30, 2022. Revised: April 29, 2024. Editorial Decision: June 29, 2024. Accepted: July 2, 2024

© The Author(s) 2024. Published by Oxford University Press on behalf of Nucleic Acids Research.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License

(<https://creativecommons.org/licenses/by-nc/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.

Introduction

Alu elements are primate-specific members of the short-interspersed element (SINE) family of retrotransposons and constitute a large fraction (~11%) of the human genome. Like other types of retrotransposons, *Alus* are subjected to tight epigenetic silencing, required to limit their inherently mutagenic mobilization (1,2). *Alu* transcription is thought to mostly depend on the RNA polymerase (Pol) III machinery, through the recognition of A- and B-box promoter DNA sequences within the transcribed region by the multi-subunit transcription factor TFIIC. The TFIIC-promoter DNA complex is bound, ~30 bp upstream of the *Alu* transcription start site (TSS), by the Pol III initiation factor TFIIB, which includes the TATA-binding protein (TBP) subunit required for initiation by all three of the eukaryotic nuclear RNA polymerases (3). Even though many *Alu* transcription units occur throughout the genome, the level of *Alu* transcription is normally kept very low by chromatin structure-based repression mechanisms (4). Recently, it has become possible to profile expression of specific *Alus* by determining the precise sequences of their transcripts, which allows mapping them to individual *Alu* genes, most of which have unique sequences due to sequence variation in a small percentage of positions (5–7). Similar advances have been reported for the expression profiling of other SINEs in mouse (8,9). Through these studies, some common features of *Alu* transcriptomes have emerged. First, in every human cell type analyzed the expressed *Alu* loci represent a very small fraction (~0.3% at most) of the total *Alu* copies in the genome. Second, the majority of *Alus* with detectable transcripts are expressed in a cell type-specific manner, while only a limited number of *Alu* elements are expressed ubiquitously. Consequently, the total number of *Alu* elements expressed in at least one cell type/tissue amounts to ~1.5% of the ~1.2 million *Alus* annotated in the human genome. Third, histone post-translational modifications associated with expressed *Alus* tend to display epigenetic marks that are typically enriched at enhancers and promoters for RNA polymerase II. These include the histone H2A variant Z (H2A.Z), indicative of repeated disassembly and re-assembly of the TSS-region nucleosomes, and histone H3 lysine 4 monomethylation (H3K4me1). This observation agrees with the hypothesis that a subset of *Alu* elements have evolved the properties of cell type-specific enhancers (7,10). Lastly, expressed *Alu* elements tend to be bound not only by the Pol III transcription machinery, but also by transcription factors typically involved in Pol II regulation, which potentially modulate *Alu* expression in a cell type-specific manner (5,7). This cell type-specific expression, as well as possible functions related to controlling Pol II enhancers, have also been reported for a small subset of mammalian-wide interspersed repeats (MIRs), the second most numerous family of SINEs in the human genome (11–13), and are increasingly recognized as a general property of transposable elements (14). A recent study further indicated that *Alu* elements contribute to human gene regulation by rewiring of the 3D chromatin architecture through an interaction network involving TFIIC, ADNP, CTCF looping and TFIIC-dependent histone H3 lysine 18 acetylation (H3K18ac) (15). Such properties may have contributed to the evolutionary impact of *Alus* and other SINEs (16).

Further pointing to the existence of highly organized chromatin at *Alu* elements, *Alus* and other SINEs typically are associated with translationally stable nucleosomes. In the case of

full-length *Alu* elements, two nucleosomes are approximately centered on the left and right arms, where they might in principle mask access to the transcriptional machinery (17,18). Such a nucleosome arrangement is likely to be instrumental to *Alu* repression, together with DNA CpG methylation and H3K9 methylation (19–21), and represents a scaffold which every activation mechanism must confront.

Alu expression is known to increase in response to different types of cell stress, such as viral infection (22,23), heat shock and cycloheximide treatment (24), as well as under altered cellular conditions that occur with some pathologies including cancer (25). Induction of SINE expression by viral infection also occurs in mouse (8). The mechanisms leading to increased *Alu* RNA levels are still largely unexplored. According to previous studies, they may be both transcriptional, involving increased chromatin accessibility (26), and post-transcriptional, due to reduced DICER-dependent turnover of *Alu* RNA (27). *Alu* upregulation upon viral infection is of particular interest, because it occurs in response to different viruses, including the dsDNA adenovirus and herpes simplex virus (23,28,29), and it reflects a general property of SINEs in different mammals (8,30–33). In the case of human adenovirus type 5 (HAdV-C5), infection of cultured human cells was found to cause *Alu* activation in different cell lines (22), possibly as the result of overcoming chromatin-mediated repression (4). This observation came in the context of a more general phenomenon of Pol III transcription activation by the Ad5 immediate early protein E1A (34,35). Studies of the mechanisms of Pol III activation by E1A identified TFIIC as a possible regulatory target of this viral oncoprotein (36,37), and identified an E1A-dependent increase in the number of active Pol III transcription complexes assembled *in vitro* with nuclear extracts from infected versus uninfected cells (38). To what extent these phenomena impact *in vivo* transcription of Pol III target genes coding for either canonical untranslated RNAs (e.g. tRNAs, 5S rRNA, U6 snRNA) or RNAs expressed from retrotransposons (*Alu* and other SINEs) has not been extensively investigated.

More recently, genome-wide studies of the effects of an E1A protein variant lacking the conserved region CR3 (referred to as small E1A, or 'e1a') revealed its surprising ability to alter global patterns of histone modifications as part of an epigenetic reprogramming process leading to cellular transformation (39,40). A pivotal role in this process is played by interactions of small e1a with key chromatin regulatory proteins such as the lysine acetylases EP300 and its paralog CREB Binding Protein (CREBBP, or CBP) and the tumor suppressor RB and related RB family members (41). Another chromatin regulator whose interaction with e1a is required for cell transformation is EP400, a SWI2/SNF2 DNA helicase-related chromatin remodeler (42). Other proteins found to be part of the same EP400 complex co-purified with E1A are the large multidomain protein TRRAP/PAF400, the TAP54 DNA helicase (RVB2), the oncogenic transcription factor MYC, actin-like proteins, the human homolog of the Polycomb protein (EPC1) (42), and the ~20 subunit TIP60 lysine acetylase complexes (43). Importantly, cellular proteins bound by the N-terminus of e1a include EP400 and TRRAP associated with a variety of related cellular multiprotein complexes with histone acetyl-transferase activity supplied by the TIP60 subunits. The TIP60/EP400 complexes are often recruited by binding of their chromodomains to H3K4me1. This can increase chromatin accessibility at enhancers by promoting incorporation of the H2A.Z histone variant (44).

To explore the breadth of the epigenetic mechanisms through which *Alus* are likely to reconcile their predominant silencing and their frequent exaptation as regulatory elements, we investigated the mechanisms of their derepression in response to adenovirus e1a expression. We surmised that e1a, by virtue of its reported abilities to reprogram the epigenome of human IMR90 primary fibroblasts and to affect Pol III-dependent transcription, would prove to be sufficient for *Alu* upregulation, thus unveiling key regulatory interactions. *Alu* expression profiling at single locus resolution, ChIP-seq characterization of histone modification and regulatory protein enrichment at expressed and silenced *Alus*, and e1a mutants specifically affected in interactions with key chromatin regulators were used together to study the complex epigenetic context operating at *Alu* transcription units.

Materials and methods

Cell culture and viruses

IMR90 primary human fetal lung fibroblasts were purchased from the American Type Culture Collection (ATCC). Cells were grown in Dulbecco's modified medium supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin and 100 µg/ml streptomycin at 37°C in 5% CO₂.

Ad5 *dl1500* containing a 9-bp deletion removing the 13S E1A mRNA 5'-splice site was described (45). The ΔE1A deletion mutant *dl312* was isolated as previously described (46). Small e1a binding mutants (e1a_{RB-b}⁻, e1a_{p300-b}⁻, e1a_{p400-b}⁻) were constructed as in (41) and afterwards incorporated into the *dl1500* background. *dl1500* and e1a binding mutant constructs were cloned into shuttle plasmid pAdlox. LoxP recombination between the HAdV-C5 backbone Ψ5 and the shuttle plasmid pAdlox, as well as propagation of viruses, were performed as described (47).

RNA extraction and total RNA-seq library preparation

IMR90 cells were grown to confluence in 60-mm Petri dishes and incubated two more days without changing the medium to arrest cells in G1/0. On the day of infection, the medium was collected (conditioned medium) and confluent cells were incubated with mock or with the indicated Ad5-based vectors for 1 h in PBS. At the end of the infection, cells were washed and transferred back to conditioned medium. The infections were performed at multiplicity of infection (MOI) 40 for *dl1500* and *dl312*, 160 MOI for e1a_{RB-b}⁻, 60 MOI for e1a_{p300-b}⁻ and 6 MOI for e1a_{p400-b}⁻, in order to achieve comparable amounts of wt and mutant e1a protein expression as assayed by Western blotting (48). 24 hours post-infection, cells were lysed with Trizol and total RNA was extracted using Direct-zol RNA MiniPrep Plus (Zymo research). After elution, RNA was subjected to DNaseI treatment (Invitrogen), followed by inactivation for 10 minutes at 65°C in the presence of 2 mM EDTA.

For the experiment in Figure 1, total RNA (1 µg) from *dl1500*, *dl312* and mock infections (performed in duplicate) was processed using a Ribo-Zero rRNA Removal Kit (Epicentre) to remove rRNA. Total RNA-seq libraries were prepared using the Illumina TruSeq stranded RNA library Preparation kit. Libraries were sequenced using a HiSeq4000 Illumina Sequencer to obtain 100-base-long paired-end reads, using a sequencing depth of about 60 million reads per sample.

For the experiments in Figure 5, total RNA (1 µg) from wt e1a (*dl1500*), e1a_{RB-b}⁻, e1a_{p300-b}⁻, e1a_{p400-b}⁻ and mock infections (performed in duplicate) was processed using the RiboCop rRNA Depletion Kit (Lexogen), and total RNA-seq libraries were prepared as described above. Libraries were sequenced using a NovaSeq Illumina sequencer to obtain 150 base-long stranded paired-end reads, using a sequencing depth of about 100 million reads per sample.

RNA-seq reads were aligned to the GRCh38 human reference genome using STAR (49). Only uniquely mapped reads were considered for downstream analyses and subjected to counting with the featureCounts tool of the SubRead Python package (50). The pipeline for *Alu* RNA profiling was essentially as previously described (6), with some improvements to reduce the rate of false positives. Specifically, we added parameters allowing for setting the cut-off value for the ratio of the expression coverage between the *Alu* body and its upstream and downstream regions. We also added a parameter controlling the fraction of the *Alu* body sequence that should be covered by reads to enable the identification of shorter, processed *Alu* transcripts. In the present study, *Alus* identified by the pipeline were subsequently filtered for an expression coverage of at least 1000 nt, corresponding to 5 paired-end reads of length 100 nt. The union of these *Alus* from all the samples in the experiment of Figure 1 constitutes the single, comprehensive list of expression-positive *Alus* (ep*Alus*). Differentially expressed *Alu* sequences were identified using the DESeq2 package (51). *Alu* sequences with a log₂ fold-change ≥0.5 or ≤-0.5 and an adjusted *P*-value <0.05 were deemed differentially expressed.

Alu proximity to protein-coding genes

GENCODE annotation v24 (human genome assembly GRCh38/hg38) was used to analyse *Alu* distance to protein-coding genes. RepeatMasker tracks were downloaded from the UCSC Genome Browser for human genome assembly hg38. *Alu* sequences that are positioned outside of protein-coding genes (intergenic *Alu*) and *Alus* that map to introns or exons of annotated genes in an antisense orientation (antisense *Alu*) were selected to obtain the intergenic/antisense *Alu* subset (802 571 *Alu* elements). The expression of intergenic/antisense *Alus* was considered only for the elements belonging to the single, comprehensive list of ep*Alus*, whereas the remaining intergenic/antisense annotated *Alu* sequences were used as a control for unexpressed *Alus*. The presence of an *Alu* within protein-coding genes was analysed using the intersect tool of the BEDtools program package v2.29.1 (52) and custom R scripts. Enrichment analyses were performed using a two-tailed Fisher's exact test.

The transcription start site (TSS) position of protein-coding genes was extracted as the first or last nucleotide (forward or reverse strand, respectively) of the 'gene' feature in the *gtf* annotation file. The distance of *Alu* elements to the TSS was analysed using the closest tool from BEDtools (52) and custom R scripts. Gene expression was calculated as the average expression (TPM) across all samples. The difference in distribution of gene expression was determined to be statistically significant using a two-sided Wilcoxon rank-sum test. A two-tailed Fisher's exact test was used to analyse the difference between the fraction of the set of all of expression-positive *Alus* and the fraction of the set of all unexpressed *Alus* within each genomic range.

ChIP-seq analyses

ChIPs of TFIIC (GTF3C2) and BDP1 were performed using procedures and antibodies described in (15) and references therein (53,54). All data was aligned to the hg38 human genome reference (GRCh38) and processed as in (15). The average ChIP signal and heatmap profiles were visualized using the tools plotHeatmap from the deepTools package v3.5.1 (55). Sources for publicly available ChIP-seq data are detailed in the Data Availability section.

Western blot

Cells infected with the adenovirus-based vectors were detached by scraping from a 60 mm plate and lysed in EBC buffer (50 mM Tris-Cl pH 8.0, 120 mM NaCl, 0.5% NP-40) with Roche cOmplete™ protease inhibitor cocktail. Samples were prepared in Laemmli buffer and heated for 5 minutes at 65°C. Protein extracts were resolved in a 9% SDS-polyacrylamide gel and electrotransferred to a polyvinylidene difluoride (PVDF) membrane. Blocking was performed in 5% skim milk in TBS-Tween 0.1% for 10 minutes. Extracts were probed with antibodies against E1A (anti-e1a MAAb M73) (56), Ku86 H-300 (sc-9034; Santa Cruz) and p400 (Thermo Fisher A300-541A) at manufacturer recommended dilutions for 1 h at room temperature or O/N at 4°C. Membranes were washed 3 times with TBS-Tween 0.1% for 10 min at room temperature. Incubation with secondary antibodies was performed using anti-mouse or anti-rabbit IgG antibodies (Bio-Rad) in TBS-Tween 0.1% buffer with 5% skim milk for 1 h at room temperature. Membranes were washed three times with TBS-Tween 0.1% for 10 min at room temperature before visualization with the Pierce ECL Western Blotting substrate (Thermo Fisher).

siRNA EP400 knockdown

Dharmacon SMART ON-TARGETplus pool siRNA against human EP400 (L-021272-05-0005) and D-001810-10-05 ON-TARGETplus Non-Targeting Pool were used to carry out EP400 knockdown in IMR90 cells. Cells were seeded in the absence of antibiotics and culture for 16h prior to transfection with lipofectamine (Lipofectamine 3000, Invitrogen). siRNAs were used at 30 nM and cells were left in culture for 24 h in the presence of the siRNA, followed by adenoviral *dl1500*- and *e1a_p400-b*- and mock-infection for other 24 h. The knockdown efficiency was evaluated by RT-qPCR after total RNA extraction (Trizol) and reverse transcription to obtain cDNA. Knockdown efficiencies of EP400 were around 50–60% depletion in different experiments. Interferon response was monitored by RT-qPCR of STAT1 and IFIT2 expression.

Reverse transcription and real-time PCR

RNA extracted from infected cells (500 ng) was reverse-transcribed using SuperScript III Reverse Transcriptase (Thermo Fisher) with random hexamer primers. The Real Time PCR reaction was performed using 20 ng of cDNA and the PowerUp SYBR Green Master Mix (Applied Biosystems), in a 20 μ l final volume with 300 nM primer concentration. Runs were performed using a 7500 Real-Time PCR System (Applied Biosystems). Expression levels were normalized using U1 snRNA as internal control and the $\Delta\Delta$ Ct method was used to evaluate expression relative to mock-infections. Data are presented as an average of two replicates \pm standard

deviation. Expression levels of *Alus* for siRNA knockdown experiments were calculated using $\Delta\Delta$ Ct (siEP400-siCTRL) method for each infection and compared to respective non-siRNA infections relative to mock. Primers used are listed in [Supplementary Table S1](#).

TF binding motif analysis

DNA sequences upstream of expression-positive *Alus* (200 bp) were analysed using Analysis of Motif Enrichment (AME) from the MEME suite (57). The Jaspar 2020 collection was used as motif database (58) and the DNA sequences of 200 bp upstream of 20 000 random unexpressed *Alus* were used as a control.

Results

Small E1A upregulates *Alu* transcription in human fibroblasts

To investigate alterations in *Alu* expression caused by adenovirus e1a, we performed *Alu* expression profiling in contact-inhibited, G1-arrested IMR90 primary human fibroblasts infected with HAdV-C5 mutant *dl1500*, which expresses e1a with little or no expression of other viral genes, versus infection with HAdV-C5 mutant *dl312*, with deletion of the complete e1a coding region (46). Mock-infected cells subjected to the same changes in medium, but without the addition of virus, served as a further control. *Alu* expression before and after infection was evaluated by RNA-seq through an analysis enabling quantitation of the expression of individual *Alu* elements to profile *Alu* expression at single-locus resolution (5,6). To minimize detection of bystander *Alu* RNA embedded within longer, Pol II-dependent transcripts, the analysis was restricted to *Alus* that are not within any annotated protein-coding or ncRNA gene (intergenic) and *Alus* that map to introns or exons of annotated genes in an antisense orientation (antisense). Most of the members of this intergenic/antisense *Alu* subset, amounting to 802 431 *Alu* elements, are likely to represent independent Pol III transcription units, and are thus more suitable than the complete genomic *Alu* inventory for evaluating a possible *Alu* transcriptional response to e1a.

As shown in Figure 1A, the *Alu* transcriptome expanded considerably in response to e1a expression. 1783 different *Alus* were detected as expressed 24 h after infection with *dl1500*, versus 973 in mock-infected and 974 in *dl312*-infected cells. More precisely, 666 more *Alus* could be detected as expressed in *dl1500*-infected cells compared to *dl312*/mock-infected cells. From now on, we will refer to the entire set of *Alus* whose expression is detected in at least one of the three conditions as ‘expression-positive’ *Alus* (ep*Alus*). We prefer this term, instead of simply ‘expressed’ *Alus*, because it indicates that an *Alu* element which is not expressed in just one or two conditions is nevertheless well distinguishable from the much larger number of *Alus* that are not expressed in any of the conditions. In general, we observed a >75% overlap between the two replicates of each infection ([Supplementary Figure S1](#)). The global effect of e1a on *Alu* expression can be observed in the profiles in Figure 1B, showing a ~4-fold increase in average *Alu* expression in response to e1a expression. The viral e1a protein is thus able to derepress *Alu* elements genome-wide, likely as a part of its global epigenome reprogramming properties. As it is further evident from Figure 1A, *dl312*- and mock-infected cells are




Figure 1. Upregulation of *Alu* expression by e1a in IMR90 cells. **(A)** Venn-diagram showing the number of expressed *Alu* elements in *dl1500*-, *dl312*- and mock-infected cells. The whole experiment was performed in duplicate. Expressed *Alus* included elements whose expression was detected by the pipeline in at least one replicate. **(B)** Average *Alu* expression profiles in the presence/absence of e1a, generated from normalized read counts (Counts Per Million, CPM) of the 1805 expression-positive *Alus*. Shown in the lower part of the panel is the structure of a typical full-length *Alu* element. The approximate positions of the A and B box internal control regions (yellow bars) are indicated above, those of internal and terminal poly(dA) motifs are indicated by white bars. The approximate position and extension of *Alu* internal sequence elements are indicated below (bp, base pairs). The upper graph reports the average read count for both replicates of each sample (*dl1500*, *dl312* and mock), labelled by different colours as indicated. The vertical dashed line marks the position of the *Alu* transcription start site (TSS). **(C)** Base resolution expression profiles, shown as Integrated Genome Browser views (119), of 4 *Alu* representative of different types of response to e1a. For the *Alu* in the first view on the left (*AluSp_chr4*), no substantial expression changes were observed under the different conditions. The *Alu* in the second view from the left (*AluSq2_chr6*) is detected as expressed in *dl312*- and mock-infected cells and its expression is strongly increased by e1a. The expression of the *Alu* in the third view from the left (*AluSp_chr8*) is only detected in *dl1500*-infected cells. The rightmost view (*AluSx1_chr9*) illustrates one of the very few examples of e1a-dependent downregulation. Orange boxes represent the orientation of repetitive elements as evidenced by the RepeatMasker track. The chromosomal coordinates of each annotated *Alu* are shown above each view. Bigwig RNA-seq data are normalized as Counts Per Million. The profiles of both replicates on (+) and (-) strands are shown for each sample (mock-, *dl312*- and *dl1500*-infected cells).

Table 1. Subfamily distribution of expression-positive *Alu*^a

| | <i>AluJ</i> | <i>AluS</i> | <i>AluY</i> | No family | Tot |
|-----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|--------------|---------|
| Annotated | 213 441 (26.6%) | 484 941 (60.43%) | 100 903 (12.57%) | 3146 (0.39%) | 802 431 |
| Expressed (<i>dl1500</i>) | 187 (10.49%) | 1499 (84.07%) | 96 (5.38%) | 1 (0.05%) | 1783 |
| Subfamily enrichment ^b | 0.39 | 1.39 | 0.43 | | |
| <i>P</i> -value ^c | <i><2.2 × 10⁻¹⁶</i> | <i><2.2 × 10⁻¹⁶</i> | <i><2.2 × 10⁻¹⁶</i> | | |
| Expressed (<i>dl312</i>) | 155 (15.91%) | 748 (76.8%) | 70 (7.19%) | 1 (0.1%) | 974 |
| Subfamily enrichment | 0.60 | 1.27 | 0.57 | | |
| <i>P</i> -value | <i>2.3 × 10⁻¹⁵</i> | <i><2.2 × 10⁻¹⁶</i> | <i>6.9 × 10⁻⁰⁸</i> | | |
| Expressed (mock) | 153 (15.72%) | 750 (77.08%) | 69 (7.09%) | 1 (0.1%) | 973 |
| Subfamily enrichment | 0.59 | 1.28 | 0.56 | | |
| <i>P</i> -value | <i>6.8 × 10⁻¹⁶</i> | <i><2.2 × 10⁻¹⁶</i> | <i>3.9 × 10⁻⁰⁸</i> | | |

^aReported for each *Alu* subfamily (columns) is the absolute number of intergenic/antisense *Alu*s and (in parentheses) their percentage. In the first row, the subfamily distribution of annotated *Alu*s is reported. The other rows report the subfamily distribution of *Alu*s expressed in *dl1500*, *dl312* and mock-infected IMR90 cells.

^bFor each sample, the subfamily enrichment was calculated as the ratio between the percentage of each subfamily out of all expressed *Alu*s and the percentage of each subfamily out of all annotated *Alu*s.

^cThe *P*-value for subfamily enrichment (in italics) was calculated using a two-tailed Fisher's exact test.

characterized by an incomplete overlap of expressed *Alu* sets, which may result from the interaction of cellular and viral receptors and the exposure of viral nucleic acids during the injection of viral DNA-protein complexes from the cell surface into the nucleus (59). However, most of these elements were also expressed in *dl1500*-infected cells, where many of them were upregulated. Of 1805 observed ep*Alu*s, almost 37% were exclusive to *dl1500*-infected cells, ~62% were also expressed in *dl312*/mock cells, whereas only ~1% were detected in *dl312*/mock-infected cells but not in *dl1500*-infected cells. Among the 953 *Alu*s expressed in both *dl312*- and *dl1500*-infected cells, 385 were differentially expressed with FDR < 0.05. With just one exception, all differentially expressed *Alu*s were upregulated in *dl1500*-infected cells. The coordinates of ep*Alu*s, including information on differentially expressed *Alu*s and the corresponding expression values are reported in [Supplementary Table S2](#).

In agreement with previous studies showing that only a small fraction of *Alu* elements is expression-positive in each cell type (5,7), ϵ 1a-dependent *Alu* upregulation was very limited on a genome-wide scale. Only 0.22% of the total intergenic/antisense *Alu* sequences could be detected as expressed after *dl1500* infection, which nonetheless represented a remarkable increase with respect to the percentage of constitutively expressed *Alu* loci (0.12%) (see Table 1). Such low percentages might also reflect the detection limits of the technique. A few examples of individual *Alu* expression profiles, representative of different ϵ 1a effects on *Alu* expression, are shown in Figure 1C.

Alu elements are classified into three main subfamilies, called *AluJ*, *AluS* and *AluY*, with *AluY* being the evolutionarily youngest, and thus the less degenerate in sequence. Accordingly, *AluY* is the only known subfamily which is at present actively retrotransposing in the human genome (60). Despite their retrotransposition activity, *AluY* elements were not found to be more expressed than the other two subfamilies in previous studies (5,7). We thus investigated the contribution (in terms of ep*Alu* fraction) of *AluJ*, S and Y subfamilies to the total expression of *Alu* sequences in IMR90 cells subjected or not to ϵ 1a-dependent reprogramming. As detailed in Table 1, a highly significant enrichment in *AluS* subfamily elements was observed among expressed *Alu*s in both control and *dl1500*-infected cells, while *AluY*- and *AluJ*-derived transcripts were significantly underrepresented in *Alu* transcrip-

tomies. As recently suggested, the relatively low contribution of *AluY* to *Alu* transcriptomes is consistent with the possibility that specific repression systems tend to be more efficient on *Alu*s with higher retrotransposition-dependent mutagenic potential (7). The underrepresentation of *AluJ* transcripts might be related to the higher number of mutations accumulated in these old elements (61), making them less able to support transcription, in particular in response to ϵ 1a. An evaluation of A- and B-box promoter elements of ep*Alu*s confirmed the results of previous analyses (5), showing a substantial match with canonical tRNA gene-derived consensus sequences for the two internal control regions (A-box: TRGYnnAnnnG; B-box: GWTCRAnnC), with the exception of the last position of the A-box, which in *Alu*s is C instead of G (data not shown).

To check whether ϵ 1a-dependent derepression also occurs in other SINES in addition to *Alu*s, we analyzed the expression of mammalian-wide interspersed repeats (MIRs). With ~500 000 copies in the human genome, MIRs are the second most numerous subgroup of human SINES. As is the case for *Alu*s, it has recently been shown that only a tiny percentage of MIRs are expressed in different cell lineages (11). Out of a total of 404 371 intergenic/antisense MIRs (defined as detailed above for *Alu*s), only 137 were expression-positive, i.e. detected as expressed in at least one sample, with no evidence of *dl1500*-dependent upregulation (data not shown). The effect of ϵ 1a thus appears to be restricted to the *Alu* subgroup of human SINES.

It was recently reported that expressed *Alu* elements tend to reside closer to the transcription start sites of Pol II-transcribed genes than unexpressed *Alu*s, a property that may be associated with their ability to function as cell type-specific enhancers for nearby genes (7). To investigate the possible relevance of *Alu* expression for protein-coding gene expression in our experimental system, we first asked whether there is any bias in the distribution of ep*Alu*s between protein-coding genes and the remaining genomic regions. As shown in [Supplementary Figure S2](#), the fraction of intragenic *Alu*s (limited to those with antisense orientation) was significantly lower (and, correspondingly, the fraction of extra-genic elements was higher) for ep*Alu*s than for unexpressed *Alu*s (panel A). Furthermore, there was a significant overrepresentation of ep*Alu*s within 32 kb from the TSSs of protein-coding genes (more marked upstream than downstream of the TSS), while at distances of more than 64 kb ep*Alu*s were sig-

nificantly underrepresented (panel B). The expression levels (normalized for gene length) of protein-coding genes flanked by ep*Alus* were generally higher than those of genes flanked by unexpressed *Alus* (panel C). Altogether, these data provide general support to the idea that ep*Alus* are overrepresented in regions relatively close to the TSSs of protein-coding genes, where their expression tends to parallel the expression of nearby genes. However, we did not find evidence for differential expression of protein-coding genes paralleling the e1a-dependent induction of nearby *Alus* (data not shown).

e1a-dependent *Alu* derepression occurs through increased TFIIIC recruitment without changes in TFIIIC occupancy

Previous reports suggested that e1a affects TFIIIC activity (36,37) and that human TFIIIC can influence the epigenetic state of *Alu* elements genome-wide (15). We thus asked whether e1a induces changes in the genome-wide distribution of TFIIIC and TFIIIB in IMR90 cells, and whether such changes could explain at least in part the observed e1a-dependent *Alu* upregulation.

The genome-wide location of TFIIIC and TFIIIB in IMR90 cells in the presence or absence of e1a was assessed by ChIP-seq using antibodies targeting the 110 kDa subunit of TFIIIC and the Bdp1 component of TFIIIB. TFIIIC/TFIIIB-associated loci in IMR90 cells were classified into four combinatorial clusters according to their enrichment for TFIIIC and Bdp1 (Figure 2A). Loci of the first two clusters were characterized by the association of both TFIIIC and Bdp1, and their overlap with all repetitive elements was strongly enriched in tRNA genes (Figure 2B). Cluster 1 loci were characterized by an e1a-dependent increase in Bdp1 association, without any appreciable change in TFIIIC enrichment. An increase in both TFIIIC and TFIIIB association was instead observed at cluster 2 targets. Loci belonging to clusters 3 and 4 were generally found to be enriched in TFIIIC but not Bdp1. These two clusters turned out to be strongly enriched in SINEs, primarily *Alu* but also MIR elements (Figure 2B). The presence of human TFIIIC in the absence of other components of the Pol III machinery has previously been reported to occur at SINE loci (62,63). A distinctive feature of cluster 4 is an e1a-dependent decrease of TFIIIC association. Genomic Regions Enrichment of Annotations Tool (GREAT) analysis (64) found that the *Alus* of this cluster are significantly associated with genes involved in embryonic lethality (Supplementary Figure S3A), suggesting that e1a-dependent TFIIIC removal from these sites might participate in viral manipulation of cell identity and differentiation pathways (40,41,65).

The analyses reported in Figure 2A and B related to TFIIIC and Bdp1 enrichment across the whole genome. To assess in a more accurate and sensitive way whether there was a correlation between the presence of TFIIIC/Bdp1 at individual *Alu* loci and their expression, we focused the ChIP-seq data analysis on the 1805 ep*Alus*. We found that ep*Alus* were globally characterized by a significant TFIIIC association independently from the presence of e1a (Figure 2C). Therefore, *Alu* upregulation in response to e1a does not appear to involve increased TFIIIC recruitment at ep*Alus*. However, no comparable TFIIIC occupancy was observed in random *Alu* sets, considered to be representative of unexpressed *Alus*. As ep*Alus* were ranked based on their levels of expression (from

high to low) in Figure 2C, our results show marked TFIIIC occupancy for highly expressed ep*Alus* for both *dl1500*- and mock-infected cells. This suggests that TFIIIC occupancy is higher at *Alus* with higher transcriptional potential and that the presence of e1a could eventually turn this potential into active transcription.

No specific signal was observed at ep*Alus* in mock-infected cells through Bdp1 ChIP-seq analysis, while a specific Bdp1 association profile at ep*Alus* was detected in *dl1500*-infected cells (Figure 2C), although it was weaker than the TFIIIC signal, possibly due to low efficiency of immunoprecipitation elicited by anti-Bdp1 antibodies and to the generally low level of *Alu* transcription activation. When the Bdp1 enrichment analysis was limited to differentially expressed *Alus*, and more specifically to those among them whose expression levels in the presence of e1a falls in the first quartile, a clear increase in Bdp1 enrichment was observed at an upstream position where TFIIIB is expected to be recruited by DNA-bound TFIIIC (Figure 2D). The Genome browser profiles of TFIIIC/Bdp1 occupancy along with expression profiles for three *Alus* included in the heatmap of Figure 2D are also reported (Supplementary Figure S3B). Altogether, the data suggest that *Alu* upregulation by e1a does not entail increased TFIIIC occupancy but does involve increased Bdp1 (and thus very likely TFIIIB) recruitment on an appreciable subset of ep*Alus*.

Epigenetic signatures of expression-positive and e1a-upregulated *Alu* elements

Since *Alu* expression control is supposed to be mainly epigenetic, with the vast majority of *Alus* undergoing chromatin-mediated silencing (2), we asked whether some key histone modifications, as well as the association of chromatin regulatory proteins, could be associated with ep*Alus*, and whether they are affected by e1a. We first made use of publicly available nucleosome mapping of IMR90 cells (66), which showed clear evidence for two strong nucleosomes positioned not only on ep*Alus*, but also on random *Alu* sets (Supplementary Figure S4, panel A). As revealed by ATAC-seq analysis of the same cells (67), however, ep*Alus* displayed more accessible chromatin upstream of TSS than random unexpressed *Alus* (Supplementary Figure S4, panel B). These preliminary observations prompted us to search for patterns of histone modifications at ep*Alus*.

To gain insight into the epigenetic state of *Alus* and its possible e1a-induced changes, we employed ChIP-seq analysis of IMR90 cells, either mock- or *dl1500*-infected, for the following histone modifications: H3K9ac, H3K18ac, H3K27ac and H3K4me1 (the last three modifications being landmarks of enhancers). As shown in Figure 3A, the most noticeable e1a-dependent changes in the average profiles at ep*Alus* were observed for H3K27ac, which was generally depleted in the presence of e1a, and for H3K4me1, whose presence upstream of ep*Alus* was generally increased in response to e1a. More subtle and less specific changes in enrichment profiles were observed for H3K9ac and H3K18ac. The comparison of histone modification profiles of ep*Alus* with random *Alu* sets revealed clear differences between expressed and unexpressed *Alus* in H3K4me1 and H3K27ac profiles. This supports the idea that ep*Alus* bear enhancer-like chromatin marks and are epigenetically remodeled by e1a towards a state marked by H3K4me1 but lacking H3K27ac, reminiscent of poised enhancers (10).




Figure 2. Genome-wide location analysis of TFIIC and TFIIB in the presence/absence of e1a. **(A)** Heatmap of TFIIC (GTF3C2) and Bdp1 spanning ± 1 kb across all TFIIC-bound sites in mock- and *d/1500*-infected cells. Clusters 1 to 4 were created by combinatorial clustering of the two factors across all regions bound. Color bar scale with increasing shades of color stands for increasing enrichment (normalized read tags). **(B)** Shown on the left is the word cloud analysis of repetitive elements associated with regions occupied by TFIIC and Bdp1 in the four clusters. Font size reflects enrichment for the indicated term. Reported on the right are the results of *sitopro* analysis (120) of TFIIC and Bdp1 enrichment (normalized read tags) for each cluster reported in panel A. Enrichment is shown spanning 2 kb from the center of the peaks. **(C)** Shown in the upper part of the panel are the average ChIP-seq enrichment profiles (normalized read tags) of the TFIIC 110 kDa subunit (left) or the Bdp1 component of TFIIB (right) in either mock-infected or *d/1500*-infected IMR90 cells across the 1805 *epAlus* and across random *Alus*. Reported below the plots are heatmaps of TFIIC and Bdp1 enrichment at the same *Alus*, sorted according to their expression level in *d/1500*-infected cells (top, high expression; bottom, low expression). **(D)** Enrichment profiles (normalized read tags) of TFIIC and Bdp1, in either mock-infected or *d/1500*-infected IMR90 cells, at differentially expressed *Alus* whose expression levels in the presence of e1a falls in the first quartile (Q1 DE *epAlu*), sorted according to their expression level in *d/1500*-infected cells (top, high expression; bottom, low expression).




Figure 3. Histone modification and chromatin regulator enrichment profiles of *epAlus* in the presence/absence of *e1a*. **(A)** Shown in the upper graphs are the average ChIP-seq enrichment ($-\log_{10}$ of the Poisson P -value) profiles of (from left to right) H3K18ac, H3K9ac, H3K27ac and H3K4me1 across the 1805 *epAlus* in either mock-infected or *dl1500*-infected IMR90 cells. Reported below the plots are the heatmaps of the same histone modification enrichments, with *epAlus* and random *Alus* ranked according to enrichment expressed as $-\log_{10}$ of the Poisson P -value. **(B)** Shown in the upper part of the panel are the average ChIP-seq enrichment profiles ($-\log_{10}$ of the Poisson P -value) of EP300 (left) and RB1 (right) in either mock-infected or *dl1500*-infected IMR90 cells across the 1805 *epAlus* and across random *Alus*. Reported below the plots are heatmaps of EP300 and RB1 association to the same *Alus*, sorted according to their expression level in *dl1500*-infected cells (top, high expression; bottom, low expression).

Given the importance of *e1a*-EP300 and *e1a*-Rb interactions for *e1a*-dependent epigenome reprogramming (41), we also investigated by ChIP-seq the enrichment and possible redistribution of these two proteins at *Alu* loci. *EpAlus* were generally characterized by the presence of a p300 peak just upstream of the *Alu* body (Figure 3B). As in the case of TFI-IIC, however, the average p300 association profile was not dramatically affected by *e1a* (Figure 3B). A similar behavior

was observed for RB1, with a peak at the same position as the p300 peak (Figure 3B). Remarkably, the p300 and the RB1 association profiles were not present when random sets of *Alus* were compared with *epAlus*, thus pointing to a relevant role of these proteins in establishing the chromatin state of *epAlus*. Importantly, *epAlus* characterized by higher expression levels in *dl1500*-infected cells (top positions in the heatmaps) also generally displayed higher p300 and RB1 occupancy both in

dl1500- and in mock-infected cells (Figure 3B). Therefore, as in the case of TFIIC, the presence of p300 and Rb proteins appears to correlate with the *Alu* transcriptional potential.

Transcription factor signature of *epAlu*s

A number of transcription factors (TFs) have previously been shown to be enriched at expressed *Alu* elements (5,7), and the evolution of *Alu* elements towards enhancers has been suggested to be accompanied by the acquisition of TF binding sites over evolutionary timescales (10). To gain insight into the possible contribution of specific TFs to the epigenetic state of *epAlu*s and their e1a-dependent upregulation, we searched for TF binding motifs enriched in the 200-bp region upstream of *epAlu*s through the Analysis of Motif Enrichment (AME) tool (68). As shown in Figure 4A, the most significant enrichment was for motifs recognized by the Fos- and Jun-related factor heterodimers collectively referred to as AP-1 (69). In order of significance, the first AP-1-unrelated TF binding motif found to be enriched upstream of *epAlu*s was the one recognized by TEAD1. Remarkably, TEAD2, TEAD3 and TEAD4 motifs were also significantly enriched. Other enriched motifs included those recognized by Nuclear Factor I (NFI), CCCTC-binding factor (CTCF), Zinc finger and BTB domain-containing protein 7A (ZBTB7A), ETS Variant Transcription Factor 6 (ETV6), Basic Helix-Loop-Helix family member A15 (BHLHA15) and CCAAT Enhancer Binding Protein Epsilon (CEBPE). Some of these TFs or TFs of the same family (namely AP-1, CTCF, CEBPB), as well as the corresponding binding motifs, were previously found to occupy loci of expressed *Alu*s in several cell lines (5,7). To further characterize the role of closely bound TFs in *Alu* expression, we took advantage of the Cistrome ToolKit (70) to perform an unbiased search for DNA binding proteins enriched, in any cell type or tissue, at the set of *epAlu*s identified in this study (Figure 4B). We found that, in addition to components of the basal Pol III transcription machinery (POLR3D, POLR3A, GFT3C2, GTF3C5, TBP), the top 20 factors displaying the highest-ranking scores for *epAlu*s included chromatin proteins and TFs whose presence suggests a complex regulatory scenario. Indeed, all three components of the ChAHP complex (CHD4, ADNP, CBX3), recently proposed to counteract CTCF binding by competing for the same sites in correspondence of mouse B2 SINES (71), were found (Figure 4B). Importantly, we also identified TFs and chromatin regulators expected to be recruited to the enriched regulatory motifs of Figure 4A, such as: YAP1 (or YAP), a coactivator acting together with the paralogous TAZ protein to regulate target genes mainly through binding to DNA-bound TEAD TFs (72), and recently shown to be affected by e1a (73); bromodomain-containing protein 4 (BRD4), known to be physically engaged genome-wide by YAP/TAZ (74); the AP-1 subunits JUN and FOSL1; CEBPB, whose binding site specificity is the same as CEBPE (Figure 4B). As this analysis used ChIP-seq data from a wide range of cell types and tissues, we wanted to gain more insight into the relevance of these observations for the regulatory properties of our IMR90 *epAlu*s. We thus further focused on publicly available CEBPB, FOS, YAP1 and BRD4 ChIP-seq data in IMR90 cells (75–79). We calculated the enrichment for all these ChIP-seq over the IMR90 *epAlu*s. Our analysis unveiled a clear enrichment for YAP1, CEBPB and FOS peaking at the *epAlu* upstream region (Figure 4C), precisely where the corresponding binding sites were revealed by the DNA motif analy-

sis. BRD4 was also found to be specifically enriched upstream of *epAlu*s, while no corresponding signals were detected for random *Alu*s (Figure 4C). Some representative profiles, showing the TF enrichment upstream of individual *epAlu*s, are reported in Supplementary Figure S5.

Interaction of e1a with chromatin remodeler EP400 is required for *Alu* upregulation

The above analyses revealed a complex epigenetic infrastructure at *epAlu*s but did not provide direct information on the molecular mechanism of e1a-dependent *Alu* upregulation. To address this issue, we analysed the functions of e1a interactions with host proteins by taking advantage of e1a mutants that are specifically impaired in their ability to interact with either RB-family proteins, EP300 and its paralog CREBBP, or EP400 (41,80,81). These mutants will henceforth be referred to as e1a_{RB-b⁻}, e1a_{p300-b⁻} and e1a_{p400-b⁻} (b⁻ standing for ‘binding minus’).

Alu expression profiling was carried out through RNA sequencing of IMR90 cells infected with the three e1a mutant strains, compared to cells infected in parallel with mock- or *dl1500*. We first identified the proper MOI for the different mutants to obtain similar amounts of e1a protein with the different strains. RNA-seq and Western blot confirmed the proper expression of e1a binding mutants, with e1a_{RB-b⁻} expressed at significantly lower levels (Supplementary Figure S6). Samples from two rounds of infections performed as biological replicates were subjected to RNA-seq analysis. We then calculated *Alu* differential expression upon infection observed for each of the four e1a variants compared to mock-infected cells and reported the results as a heatmap (Figure 5A). Despite the lower expression levels of e1a_{RB-b⁻}, a slightly higher number of differentially expressed *Alu*s were observed in its presence compared to wt e1a. A reduction in the number of differentially expressed *Alu*s was instead observed with e1a_{p300-b⁻} and, much more markedly, with e1a_{p400-b⁻}. Therefore, RB-family proteins (RB, RBL1 and RBL2) appear to exert at best a negative modulatory effect on e1a-dependent *Alu* upregulation. By contrast, EP300/CREBBP appear to act positively in the same process, in accordance with their reported stimulatory activity on Pol III chromatin templates (82). But the major e1a function required for *Alu* derepression turned out to be the interaction with EP400, whose involvement in the regulation of *Alu* or any Pol III-transcribed gene has not been previously reported. Of the *Alu*s activated by wt e1a, ~90% were no longer activated by its mutant defective in EP400 binding.

The effect of the e1a mutations on *Alu* expression regulation was further confirmed by RT-qPCR on two individual *epAlu*s whose unique 3'-trailer sequence was long enough to allow for unambiguous detection of *Alu* transcripts from the individual loci (Figure 5B, upper panel). Expression profiles of the same RT-qPCR tested loci reconstructed from RNA-seq data supported the same conclusion (Figure 5B, lower panel). For these two *Alu*s, upregulation was strongly impaired with e1a_{p400-b⁻}, and it was also negatively affected, to a lower extent, by the loss of e1a interaction with RB and EP300/CREBBP (the behaviour of RB at these *Alu*s thus deviates from the generally observed one). In contrast to these effects of e1a and its interaction mutants on *Alu* expression, no e1a-dependent expression modulation was observed for other non-*Alu* Pol III transcripts (7SL RNA, 7SK RNA, U6 snRNA,




Figure 4. TF binding motifs and ChIP-seq enrichment at epAlu. **(A)** TF binding motifs enriched in the 200 bp upstream of the TSS of epAlu with (right column) their corresponding *P*-values adjusted for multiple testing with Bonferroni correction. **(B)** Cistrome Toolkit (<http://dbtoolkit.cistrome.org/>) analysis of epAlu and random Alu sets. Gigggle score is calculated by using the genome coordinates of the two sets of Alus to retrieve which factors bind those intervals among all curated experiment in the Cistrome database (70). **(C)** Plotheatmap of ChIP-seq of YAP1, CEBPB, FOS and BRD4 at the 1805 epAlu and at random Alus based on data from (75–79). Ranking is according to enrichment of YAP1 reported as $-\log_{10}$ of the Poisson *P*-value.

RNase P RNA, tRNA^{His}) whose genes are characterized by different types of promoter organization (83) (Figure 5C-D). As e1a-dependent Alu upregulation was found to entail increased Bdp1 recruitment (Figure 2), we wondered whether the weakening of Alu activation caused by the loss of e1a-EP400 interaction could be due to reduced Bdp1 recruitment. We thus employed Bdp1 ChIP-seq to systematically address whether Bdp1 enrichment at dl1500-differentially expressed Alus and epAlus was affected genome-wide by expression of

e1a_p400-b⁻. By comparing Bdp1 enrichment profiles upon infection of IMR90 with dl312 (no e1a), dl1500 (wt e1a) and the e1a_p400-b⁻ mutant, we found that infection with the latter led to a significant decrease in Bdp1 recruitment at both set of Alus (Figure 5E and F).

To find support for a general role of EP400 in Alu epigenetic control, we took advantage of the availability of ChIP-seq data for EP400 in K562 cells (84). Even though IMR90 and K562 represent different cell lineages and thus display




Figure 5. Dependence of *Alu* upregulation on e1a interaction with chromatin regulators. **(A)** Heatmap showing increased (red) or decreased (blue) expression of *Alu* elements triggered by wt e1a or e1a mutants defective in interaction with RB (e1a_{RB}⁻), p300 (e1a_{p300}⁻) or p400 (e1a_{p400}⁻), as compared to mock-infected cells. Boxed above each heatmap are the numbers of differentially expressed *Alus* (log₂ fold-change ≥ 0.5 or ≤ -0.5 and an adjusted *P*-value < 0.05). The experiment was performed in two biological replicates. **(B)** Expression levels of two individual *Alus* as measured by RT-qPCR (upper graphs) and RNA-seq (lower views). Fold changes estimated by RT-qPCR are relative to the expression in mock-infected cells, after normalization to U1 snRNA gene expression. Primers were chosen to target the unique sequence of *Alu* elements within the 3' trailer region. RT-qPCR data relative to each independent experiment are represented as dots. Indicated by horizontal bars are the means ± standard deviation between the replicates. RNA-seq data (lower subpanels) are presented as genome browser views of the same *Alu* elements analysed in the upper plots. Orange boxes represent the orientation of repetitive elements as evidenced by the RepeatMasker track. The chromosomal coordinates of each annotated *Alu* are shown in the upper part of each subpanel. Bigwig tracks are normalized per CPM. **(C)** Expression changes of 7SL RNA (left graph) and U6 snRNA (right graph) genes induced by either wt e1a or e1a_{p400}⁻ mutant, as measured by RT-qPCR. Fold change is relative to mock-infected cells, after normalization to U1 snRNA gene expression. RT-qPCR data from each of two independent experiments are represented as dots. Indicated by horizontal bars are the means ± standard deviation between the replicates. **(D)** Genome browser views of the expression of RN7SL1, RPPH1, tRNA-His-GTG-1-1 (GtRNA^{Gly}), RNU6-9 and RN7SK genes, coding for 7SL RNA, Ribonuclease P RNA component H1, tRNA^{Gly}(GGA), U6 snRNA and 7SK RNA, respectively. Expression profiles are based on RNA-seq analysis of IMR90 cells infected as indicated on the left. **(E)** Heatmap and enrichment profiles (normalized read tags) of Bdp1 ChIP-seq occupancy at differentially expressed *Alus* (DE ep*Alus*) and ep*Alus* in IMR90 infected with *dI312*, *dI1500* and p400b⁻ viruses. **(F)** Genome browser views Bdp1 ChIP-seq data of two highly *dI1500*-induced *Alu* elements as evidenced by the RepeatMasker track. The chromosomal coordinates of each annotated *Alu* are shown above each view. Bigwig tracks are normalized for the library size.

largely different sets of expression-positive *Alus*, we observed nevertheless that 285 *Alus* are expression-positive in both cell lineages (Supplementary Figure S7A). Both the Pol III machinery and EP400 turned out to be strongly enriched at these *Alus* in K562 cells (Figure 6A). When the whole set of IMR90 ep*Alus* was considered, EP400 enrichment was still significant (Mann–Whitney *U* test), while no enrichment signal was observed with random *Alu* subsets of similar size (Figure 6B, left subpanel). When the same analysis was carried out on the subset of *Alus* that are expression-positive in K562 cells, as expected EP400 was found to be even more enriched (Figure 6C, left subpanel). As EP400 has been implicated in the deposition of H2A.Z histone variant at nucleosomes (85), with the potential to influence both transcription and DNA repair, we compared the H2A.Z ChIP-seq profiles at expression-positive *Alus* of K562 cells and found an appreciable enrichment of H2A.Z compared to a random set (Figure 6B–C, right subpanels). To gain more mechanistic insight into the function of EP400 at *Alus* upregulated by ϵ 1a, we implemented siRNA knockdown of EP400 prior to infection with *dl1500* and ϵ 1a_p400-b⁻ adenovirus (Figure 6D–E, Supplementary Figure S7B and C). Our data show that siRNA depletion of EP400 did not cause any increase in ep*Alu* expression in mock-infected cells, thus excluding that EP400 is a mere *Alu* repressor counteracted by ϵ 1a. In contrast, EP400 depletion from IMR90 cells abrogated ϵ 1a-mediated upregulation of *AluSp* and *AluSc*, thereby attesting that EP400 is actively involved in the induction of *Alus* caused by wt ϵ 1a expression (Figure 6E). *Alu* upregulation by ϵ 1a thus critically depends on previously unrecognized epigenetic features of ep*Alus* involving the active role of p400 chromatin remodeler and possibly its histone exchange activity.

Discussion

Alu expression has long been known to be upregulated in response to viral infection (86). Our study shows that the Adenovirus 5 ϵ 1a oncoprotein is responsible by itself for derepression of several hundred *Alu* elements across the human genome in IMR90 fibroblasts by virtue of its interaction with the host ATPase chromatin remodeler EP400. Our data show that many of the ϵ 1a-responsive *Alus* display features of YAP/TAZ- and AP-1-associated enhancers where ϵ 1a appears to reconfigure key histone modifications, most notably H3K27 acetylation. These effects can best be framed into the context of ϵ 1a epigenome reprogramming properties required for maximal viral DNA replication in permissive human cells and cell transformation of baby rat kidney cells (40). An impressive range of interactions with host proteins is exploited by ϵ 1a to induce cell cycling and dedifferentiation (87). Two of the best well-characterized ϵ 1a-host protein interactions take place with the tumour suppressor RB1 and the lysine acetyltransferases EP300/CREBBP. These interactions are key to the ϵ 1a-induced gene dysregulation underlying cell transformation. Their mechanistic contribution to this process has been widely studied and shown to involve, in addition to the displacement of RB1 from E2F transcription factors, a complex interplay with chromatin regulatory proteins (41,88–91). The less extensively investigated ϵ 1a-EP400 interaction has been known for twenty years to function in the ϵ 1a transforming process (42), and later was shown to stabilize MYC and to promote formation of MYC-EP400 complexes on chromatin leading to activation of MYC target genes (92).

Our finding that derepression of a subset of ep*Alus* strongly depends on the ϵ 1a-p400 interaction adds an important element to our knowledge of ϵ 1a-dependent epigenome reprogramming, by showing that it might also rely on the exploitation of a chromatin remodeler at a subset of retrotransposons. Whether such an epigenetic switch, operating at hundreds of loci throughout the genome, also involves the MYC family of transcription factors, or some other EP400-interacting proteins like TRRAP, remains to be established. In support of a possible involvement of Myc proteins, N-Myc was recently shown to interact with TFIIC by proteomic analysis and to colocalize with TFIIC at thousands of sites (93). c-Myc was also previously found to activate Pol III-dependent transcription of tRNA and 5S rRNA genes through a mechanism involving TRRAP and Gcn5 recruitment (94) and more generally to be present at Pol III-transcribed genes at the genome-wide scale (95). TRRAP recruitment was also previously reported to be required for cell transformation by E1A (96). Myc proteins could therefore participate in the complex interaction network exploited by ϵ 1a to epigenetically deregulate *Alus*.

Through its histone exchange activity, EP400 is likely to promote H2A.Z deposition at ep*Alus*, whose enrichment was correlated with *Alu* expression in this and previous studies (7). Notably, we find that EP400 is actively involved in wt ϵ 1a induction of *Alus* in agreement with findings reporting EP400 to be necessary for H2A.Z and H3.3 deposition into enhancers and promoters *in vivo* (97). Another possible mechanistic facet of *Alu* activation through ϵ 1a-EP400 interaction is suggested by the ability of the TIP60/p400 complex to recognize H3K4me1 through its TIP60 component (44). As part of the *Alu* epigenetic switch, the ϵ 1a-EP400 interaction might favour H3K4me1-mediated TIP60/p400 recruitment, which would in turn promote *Alu* transcription. The presence at specific *Alu* loci of regulators of chromatin architecture might not be limited to p400, as another chromatin remodeler, CHD4, recently shown to associate to evolutionarily younger mouse SINEs as part of the ChAHP complex (71), was found to be enriched at a subset of *Alu* elements in human breast cancer cells (15).

The use of ϵ 1a mutants specifically defective in interaction with chromatin regulatory proteins also allowed us to exclude the possibility that ϵ 1a acts by relieving Rb-mediated repression at *Alu* elements. With an ϵ 1a mutant unable to interact with Rb, the number of upregulated *Alus* and the extent of upregulation was even higher than with wt ϵ 1a, thus suggesting that the ϵ 1a-Rb interaction impacts negatively on *Alu* expression. As to the ϵ 1a-p300 interaction, its loss only slightly weakened *Alu* expression upregulation. Collectively, these effects are in line with the complex interplay between ϵ 1a, Rb and p300 previously shown to lie behind activating and repressing chromatin conformations in Ad5-infected cells (41).

A possible key to understanding the epigenetic features of *Alu* elements, including their expression leading to *Alu* RNA, is their recently recognized nature of *cis*-regulatory elements serving as a repertoire for the *de novo* birth of enhancers (7,10). Such enhancer-like properties extend to different types of SINEs in different species, suggesting a relevant role of SINEs in the evolution of complex regulatory networks (98,99). Results in our study both confirm and expand the notion of *Alus* as enhancer-like elements. In mock-infected and ϵ 1a-expressing IMR90 cells, ep*Alus* differed for two key histone modifications, H3K4me1 and H3K27ac, whose




Figure 6. Enrichment of EP400 and H2A.Z at epAlus and effects of EP400 depletion. **(A)** ChIP-seq enrichment profiles of Pol III (RPC155 subunit), TFIIC and EP400 (p400) at the 285 *Alu* elements that are expression-positive in both IMR90 (this study) and K562 cells (76,78). Plotheatmap of ChIP-seq data. From left to right: Pol III enrichment in K562 cells, TFIIC enrichment in K562 cells, TFIIC enrichment in mock-infected and *dl1500*-infected IMR90 cells and EP400 enrichment in K562 cells. Ranking is according to enrichment of Pol III in K562 cells reported as $-\log_{10}$ of the Poisson *P*-value. **(B)** Plotheatmap of ChIP-seq enrichment of EP400 (left) and the H2A.Z histone variant (right) in K562 cells (76,78) across either the 1805 IMR90 epAlus or random *Alu*s. Ranking is according to enrichment of EP400 in K562 cells reported as $-\log_{10}$ of the Poisson *P*-value. **(C)** Plotheatmap of ChIP-seq enrichment of EP400 (left) and the H2A.Z histone variant (right) in K562 cells across either the 3764 *Alu*s detected as expressed in K562 cells or random *Alu*s. Ranking is according to enrichment of p400 in K562 cells reported as $-\log_{10}$ of the Poisson *P*-value. **(D)** Schematic representation of the protocol of siRNA-mediated EP400 knock down (KD) followed adenoviral infection (time of each incubation is reported). **(E)** RT-qPCR for measuring expression of two epAlu loci (the same as in Figure 5B) comparing mock-, e1a_p400-b⁻ and *dl1500*-infection in conditions of absence of silencing RNA (non-siRNA) or presence of siRNA against p400 (siEP400) compared to a scramble set of siRNA control (siCTRL). Standard error bars are indicated, as a result of two biological replicates.

concomitant presence is an epigenetic hallmark of active enhancers. Specifically, we observed a general $e1a$ -dependent increase of H3K4me1 and a general depletion of the H3K27ac marker. This epigenetic signature at *epAlus* in the presence of $e1a$ roughly resembles the previously reported enhancer-like *Alu* epigenetic profile reminiscent of poised enhancers, marked by H3K4me1, but lacking H3K27ac (10). The association of p300 upstream of *epAlus* is also consistent with an enhancer-like state of these elements. At these sites, however, the acetyltransferase activity of p300 towards H3K27 appears to be inhibited by $e1a$, as it occurs at many enhancers and other genomic locations as part of the epigenome reprogramming effects of $e1a$ (41). The ability of $e1a$ to alter some *Alus* towards the epigenetic state of poised enhancers, corresponding to a cellular state preceding differentiation (100), might contribute to $e1a$'s ability to promote cell dedifferentiation (73). On this regard, our finding that the YAP/TAZ coactivators associate to *epAlus* in unperturbed IMR90 cells (most likely through TEAD TFs recognizing their cognate DNA motif upstream of *epAlus*) appears as particularly relevant. As recently shown, $e1a$ causes YAP/TAZ cytoplasmic sequestration, with consequent genome-wide loss of YAP/TAZ and H3K27ac at enhancers involved in cell differentiation (73). Even though we have not addressed the $e1a$ -dependent YAP/TAZ dynamics at *epAlus*, it appears reasonable to hypothesize that $e1a$ -dependent *Alu* derepression contributes, through unexplored mechanisms, to enhancer manipulation by $e1a$. Possibly related to these mechanisms are the previously reported interaction of YAP/TAZ with EP400 and the so far unreported enrichment at *epAlus* of BRD4, which is known to mediate YAP/TAZ-dependent transcriptional regulation in cancer cells (74).

Another related issue that deserves proper investigation is the role of two other families of enhancer-associated transcription factors, AP-1 and C/EBP. We found an overrepresentation of their cognate sites upstream of expression-positive *Alus*, as well as an enrichment of members of the two TF families at *epAlus* based on ChIP-seq data analysis, an observation also reported by previous studies (5,7). AP-1 and C/EBP TFs might play a role in *Alu* transcription and/or *Alu* enhancer-like function through recruitment of coactivators like p300/CBP (101,102). However, the interplay between the presence of these factors at *epAlus* and their $e1a$ -dependent upregulation needs to be clarified, as $e1a$ was previously shown to counteract Fos-dependent transcriptional activation by competing for p300/CBP binding (103). Of note, the concomitant presence of AP-1 and YAP/TAZ/TEAD at growth-controlling enhancers was previously associated to oncogenesis (104), thus reinforcing the idea that $e1a$ -triggered *Alu* derepression participates in key cell-controlling enhancer functions. The identity of *Alu*-associated TF family members is another issue awaiting further clarification. The different isoforms of C/EBP (α , β , γ , δ , ϵ , ζ) have binding site specificities that are almost identical (with the exception of C/EBP ζ) (105). Therefore, ChIP studies can tell more reliably than DNA sequence motif analysis which isoforms are more likely to be involved than others. Remarkably, C/EBP β was previously reported to be significantly enriched at *epAlus* in HeLa, HepG2 and K562 cells based on analysis of ENCODE ChIP-seq data (5). The same association, again based on ENCODE ChIP-seq data, was observed in this study in the case of IMR90 cells. Moreover, C/EBP β (alias CEBPB) has recently been shown to mediate the Pol III-dependent transcription of a microRNA tran-

scription unit (miR-138) in human glioblastoma cell lines, and the same study provided evidence for a more general involvement of C/EBP β in the recruitment of Pol III transcription complexes to their target genes (106). Notably, all the above mentioned *epAlu*-associated TFs were found to associate with target sites located upstream of the *Alu* body, suggesting a co-evolution of *epAlus* with these TF binding sites which may be relevant for *Alu* exaptation as regulatory elements, as well as for *Alu* transcription. In fact, the internal pol III elements (A and B boxes) are likely to synergize with the upstream flanking region for *Alu* transcription (5). The mostly random insertion of *Alu* elements into the genome creates a likelihood that the majority will land in regions that do not support transcription even under epigenetically open chromatin, due to the lack of appropriate upstream sequences. This could also explain why the relative number of *epAlu* loci is so small.

Viewing *epAlus* as enhancers or proto-enhancers suggests possible implications for their expression and their virus-dependent upregulation. A key to understanding these processes may in fact be provided by the tendency of enhancers to act as templates for noncoding enhancer RNA (eRNA) synthesis in a manner linked to their activity (107). *EpAlu*-encoded RNA may possibly be considered as a special case of eRNA, with the potential to influence transcription of genes placed under the control of the *Alu* enhancer, as shown for the regulation of *FOS* gene transcription by a SINE-encoded eRNA in mouse cortical neurons (98). Moreover, a recent work has revealed that ~38% of the enhancer-promoter RNA interaction sites are overlapped with *Alu* sequences (108). It should be added, however, that *Alu*-associated TFIIC has the potential to participate in organizing the landscape of chromatin loops, and thus in controlling gene expression at distance, just by virtue of its protein-protein interactions with transcription factors and/or architectural proteins such as ADNP and CTCF (15), even in the absence of RNA production. How frequently and to what extent *Alu* transcripts, or even the mere act of their transcription, participate in the enhancer-like activity of *Alus* still awaits further investigation (see below).

Another, more general issue that has still to be satisfactorily understood is the impact of *epAlu* derepression on the processes leading to cell transformation. In principle, *Alu* RNA accumulation might contribute to sustained cell proliferation via remodulation of the mRNA transcriptome which may occur both transcriptionally and post-transcriptionally (109,110). However, the actual amount of *Alu* transcripts elicited by $e1a$ is probably low compared to the one obtained by artificial *Alu* RNA overexpression, and the duration and stability of $e1a$ -dependent *Alu* RNA increase has not been evaluated. It is therefore somewhat difficult to attribute to increased *Alu* RNA a causative role in $e1a$ -dependent cell transformation. Alternatively, the transcripts resulting from *epAlu* derepression might be considered to some extent as by-products of an epigenetic transition whose contribution to cell transformation is not due to the RNA products themselves but possibly to *epAlu*-triggered genome architectural rewiring (15).

Another property of $e1a$ with the potential to contribute to cellular transformation is its previously reported ability to increase the activity of both TFIIC and TFIIB, at least in part by overcoming the repressive effect of Rb (35,37,111). Derepressed Pol III-dependent transcription of genes coding for RNAs required for protein synthesis and trafficking, such as tRNAs, 5S rRNA and 7SL RNA, would in turn contribute to

cell transformation (112). Although our study did not address systematically the expression of canonical Pol III-transcribed genes, whose study at single-locus resolution is especially challenging for tRNA genes (113), expression analysis of a few of them showed the lack of an e1a-dependent upregulation comparable to the one of ep*Alus*. At the same time, an e1a-dependent increase of Bdp1 (but not TFIIC) association was generally observed for tRNA gene loci. According to a commonly accepted model, mainly based on *in vitro* studies, Rb sequesters a TFIIB component without associating itself to DNA. In doing so, it impairs the TFIIC-dependent recruitment of TFIIB at promoters and subsequent transcription by Pol III. By interacting with Rb, e1a would release TFIIB from repression (112). According to more recent analyses of ChIP-seq data, however, Rb stably associates to a relevant percentage of tRNA gene loci in IMR90 cells (114). This leaves open the possibility that Rb might participate in tRNA gene transcriptional regulation by influencing steps subsequent to TFIIB recruitment, as it occurs in the case of Pol III-transcribed genes with a Type 3 promoter (e.g. the U6 snRNA gene) (115).

The most evident e1a-dependent change in TFIIC enrichment occurred at a subset of TFIIC genomic targets, strongly enriched in *Alu* elements, where marked depletion of TFIIC occurred upon *dl1500* infection. This *Alu* subset overlaps only marginally to the one of ep*Alus*, thus implying that the modulation of TFIIC association to these elements does not entail changes in *Alu* expression. Rather, TFIIC depletion at these *Alu* loci might result in epigenetic changes possibly contributing to e1a interference with the cellular differentiation state, as suggested by the involvement of neighbouring genes in embryonic development.

In conclusion, molecular characterization of *Alu* upregulation in response to adenovirus infection led us to identify e1a as a key player in this phenomenon through its epigenome reprogramming properties. We uncovered an unexpectedly complex epigenetic landscape at ep*Alu* elements. In some respects, our findings confirm the idea that ep*Alus* represent a tiny subset of the whole *Alu* complement that have been -or are being- exapted to enhancer function (7,10). The observation that ep*Alus* are enriched in older *AluS* element is also suggestive of evolutionary selection. We speculate that, among the >1 200 000 *Alu* elements in the human genome, such evolutionarily exapted *Alus* are likely to constitute a small set of non-silenced elements, sharing some basic epigenetic features that endow them with a certain transcriptional potential. Different subsets of such *Alus* would then be activated in different cell types due to further epigenetic changes accompanying cell differentiation. Whether and how *Alu* transcription and its modulation by different cues mechanistically contribute to enhancer function remains to be established. The fact that some derepressed *Alus* display features of YAP/TAZ enhancers, that are known to undergo e1a-dependent inactivation, supports an inverse relationship between Pol III transcription activation and enhancer activity. This would be in contrast with a previously proposed role of enhancer SINE Pol III transcription in activating Pol II-dependent transcription of the target gene (98). Other studies, however, provided evidence for a complex interplay between Pol III and Pol II transcription at regulatory SINEs (116,117), leaving room for the possibility that at enhancer *Alus* Pol III transcription counteracts Pol II-dependent eRNA synthesis and thus enhancer activity. In other respects, our study of the ability of e1a to turn on the *Alu* epigenetic switch revealed a possible unexpected role of chromatin re-

modelling in this process, with EP400 and possibly other chromatin remodelers performing a key activating function during induction of expression-prone *Alus*. As exemplified by the subtle control of promoter-bound nucleosome positioning by ATP-dependent remodeling complexes at rRNA genes (118), chromatin remodelers offer the possibility to rapidly switch between chromatin states of different transcriptional accessibility without radically changing the overall nucleosomal architecture. They are thus likely to be key players at exapted *Alu* loci where facilitation of accessibility changes may favour the evolutionary exploration of novel regulatory possibilities.

Data availability

Data of RNA-seq and ChIP-seq generated in this study are available at GEO under accession number GSE208717. Publicly available data were retrieved from the following sources: GSE32340 for H3K4me1 ChIP-seq (*dl1500*-infected IMR90 cells) and H3K9ac ChIP-seq (40); GSE43070 for H3K4me1 ChIP-seq (uninfected IMR90 cells) (40); GSE59693 for ChIP-seq of H3K27ac, EP300, Pol II and RB (mock- and *dl1500*-infected IMR90 cells) (41); GSM2828526 for EP400 ChIP-seq (K562 cells); GSM935372 for Pol III (RPC155 subunit) ChIP-seq (K562 cells); GSM935343 for TFIIC (GTF3C2 subunit) ChIP-seq (K562 cells); GSM733786 for H2A.Z ChIP-seq (K562 cells); GSM3289968 for ATAC-seq (IMR90 cells); GSM935519 for CEBPB ChIP-seq (IMR90 cells); GSM818008 for H2A.Z ChIP-seq (IMR90 cells); GSM2825448 for FOS ChIP-seq (IMR90 cells); GSM1696207 for YAP1 ChIP-seq (IMR90 cells); GSM1915116 for BRD4 ChIP-seq (IMR90 cells).

Supplementary data

Supplementary Data are available at NAR Online.

Acknowledgements

This work used computational and storage services associated with the Hoffman2 Shared Cluster provided by UCLA Institute for Digital Research and Education's Research Technology Group. RNA-seq was performed by the Broad Stem Cell Research Center High Throughput Sequencing Core at the University of California, Los Angeles, and by Fulgent Genetics, Temple City, California). BM, GD, MM and RF have benefited from the equipment and framework of the COMP-HUB and COMP-R Initiatives, funded by the 'Departments of Excellence' Program of the Italian Ministry for University and Research (MIUR, 2018-2022 and MUR, 2022-2027), and from the HPC (High-Performance Computing) facility of the University of Parma, Italy. The authors wish to thank the CIBIO NGS Facility of the University of Trento for sequencing samples. CIBIO Core Facilities are supported by the European Regional Development Fund (ERDF) 2014-2020. Graphical Abstract created with BioRender.com.

Funding

Italian Association for Cancer Research [AIRC, IG2015-16877 to G.D., AIRC, IG2022-27712 to R.F.]; research in the A.J.B. laboratory was funded by the Professor June Lascelles Fund. Funding for open access charge: AIRC IG2022-27712; University of Parma.

Conflict of interest statement

None declared.

References

- Goodier, J.L. (2016) Restricting retrotransposons: a review. *Mobile DNA*, **7**, 16.
- Varshney, D., Vavrova-Anderson, J., Oler, A.J., Cairns, B.R. and White, R.J. (2015) Selective repression of SINE transcription by RNA polymerase III. *Mobile Genet. Elem.*, **5**, 86–91.
- Dieci, G., Conti, A., Pagano, A. and Carnevali, D. (2013) Identification of RNA polymerase III-transcribed genes in eukaryotic genomes. *Biochim. Biophys. Acta*, **1829**, 296–305.
- Russanova, V.R., Driscoll, C.T. and Howard, B.H. (1995) Adenovirus type 2 preferentially stimulates polymerase III transcription of Alu elements by relieving repression: a potential role for chromatin. *Mol. Cell. Biol.*, **15**, 4282–4290.
- Conti, A., Carnevali, D., Bollati, V., Fustinoni, S., Pellegrini, M. and Dieci, G. (2015) Identification of RNA polymerase III-transcribed alu loci by computational screening of RNA-seq data. *Nucleic Acids Res.*, **43**, 817–835.
- Carnevali, D. and Dieci, G. (2017) Identification of RNA polymerase III-transcribed SINEs at single-locus resolution from RNA sequencing data. *Noncoding RNA*, **3**, 15.
- Zhang, X.O., Gingeras, T.R. and Weng, Z. (2019) Genome-wide analysis of polymerase III-transcribed Alu elements suggests cell-type-specific enhancer function. *Genome Res.*, **29**, 1402–1414.
- Karijolich, J., Zhao, Y., Alla, R. and Glaunsinger, B. (2017) Genome-wide mapping of infection-induced SINE RNAs reveals a role in selective mRNA export. *Nucleic Acids Res.*, **45**, 6194–6208.
- Mori, Y. and Ichianagi, K. (2021) melRNA-seq for expression analysis of SINE RNAs and other medium-length non-coding RNAs. *Mobile DNA*, **12**, 15.
- Su, M., Han, D., Boyd-Kirkup, J., Yu, X. and Han, J.D. (2014) Evolution of Alu elements toward enhancers. *Cell Rep.*, **7**, 376–385.
- Carnevali, D., Conti, A., Pellegrini, M. and Dieci, G. (2017) Whole-genome expression analysis of mammalian-wide interspersed repeat elements in human cell lines. *DNA Res.*, **24**, 59–69.
- Jjingo, D., Conley, A.B., Wang, J., Marino-Ramirez, L., Lunyak, V.V. and Jordan, I.K. (2014) Mammalian-wide interspersed repeat (MIR)-derived enhancers and the regulation of human gene expression. *Mobile DNA*, **5**, 14.
- Ye, M., Goudot, C., Hoyler, T., Lemoine, B., Amigorena, S. and Zueva, E. (2020) Specific subfamilies of transposable elements contribute to different domains of T lymphocyte enhancers. *Proc. Nat. Acad. Sci. U.S.A.*, **117**, 7905–7916.
- Fueyo, R., Judd, J., Feschotte, C. and Wysocka, J. (2022) Roles of transposable elements in the regulation of mammalian transcription. *Nat. Rev. Mol. Cell Biol.*, **23**, 481–497.
- Ferrari, R., de Llobet Cucional, L.I., Di Vona, C., Le Dilly, F., Vidal, E., Lioutas, A., Oliete, J.Q., Jochem, L., Cutts, E., Dieci, G., et al. (2020) TFIIC binding to alu elements controls gene expression via chromatin looping and histone acetylation. *Mol. Cell*, **77**, 475–487.
- Ferrari, R., Grandi, N., Tramontano, E. and Dieci, G. (2021) Retrotransposons as drivers of mammalian brain evolution. *Life (Basel)*, **11**, 376.
- Li, C. and Luscombe, N.M. (2020) Nucleosome positioning stability is a modulator of germline mutation rate variation across the human genome. *Nat. Commun.*, **11**, 1363.
- Tanaka, Y., Yamashita, R., Suzuki, Y. and Nakai, K. (2010) Effects of Alu elements on global nucleosome positioning in the human genome. *Bmc Genomics [Electronic Resource]*, **11**, 309.
- Englander, E.W., Wolffe, A.P. and Howard, B.H. (1993) Nucleosome interactions with a human Alu element. Transcriptional repression and effects of template methylation. *J. Biol. Chem.*, **268**, 19565–19573.
- Kondo, Y. and Issa, J.P. (2003) Enrichment for histone H3 lysine 9 methylation at Alu repeats in human cells. *J. Biol. Chem.*, **278**, 27658–27662.
- Varshney, D., Vavrova-Anderson, J., Oler, A.J., Cowling, V.H., Cairns, B.R. and White, R.J. (2015) SINE transcription by RNA polymerase III is suppressed by histone methylation but not by DNA methylation. *Nat. Commun.*, **6**, 6569.
- Panning, B. and Smiley, J.R. (1993) Activation of RNA polymerase III transcription of human Alu repetitive elements by adenovirus type 5: requirement for the E1b 58-kilodalton protein and the products of E4 open reading frames 3 and 6. *Mol. Cell. Biol.*, **13**, 3231–3244.
- Panning, B. and Smiley, J.R. (1994) Activation of RNA polymerase III transcription of human Alu elements by herpes simplex virus. *Virology*, **202**, 408–417.
- Liu, W.M., Chu, W.M., Choudary, P.V. and Schmid, C.W. (1995) Cell stress and translational inhibitors transiently increase the abundance of mammalian SINE transcripts. *Nucleic Acids Res.*, **23**, 1758–1765.
- Yeganeh, M. and Hernandez, N. (2020) RNA polymerase III transcription as a disease factor. *Genes Dev.*, **34**, 865–882.
- Li, T.H., Kim, C., Rubin, C.M. and Schmid, C.W. (2000) K562 cells implicate increased chromatin accessibility in Alu transcriptional activation. *Nucleic Acids Res.*, **28**, 3031–3039.
- Kaneko, H., Dridi, S., Tarallo, V., Gelfand, B.D., Fowler, B.J., Cho, W.G., Kleinman, M.E., Ponicsan, S.L., Hauswirth, W.W., Chiodo, V.A., et al. (2011) DICER1 deficit induces Alu RNA toxicity in age-related macular degeneration. *Nature*, **471**, 325–330.
- Panning, B. and Smiley, J.R. (1995) Activation of expression of multiple subfamilies of human Alu elements by adenovirus type 5 and herpes simplex virus type 1. *J. Mol. Biol.*, **248**, 513–524.
- Jang, K.L. and Latchman, D.S. (1992) The herpes simplex virus immediate-early protein ICP27 stimulates the transcription of cellular Alu repeated sequences by increasing the activity of transcription factor TFIIC. *Biochem. J.*, **284**, 667–673.
- Dunker, W., Zhao, Y., Song, Y. and Karijolich, J. (2017) Recognizing the SINEs of infection: regulation of retrotransposon expression and modulation of host cell processes. *Viruses*, **9**, 386.
- Williams, W.P., Tamburic, L. and Astell, C.R. (2004) Increased levels of B1 and B2 SINE transcripts in mouse fibroblast cells due to minute virus of mice infection. *Virology*, **327**, 233–241.
- Carey, M.F., Singh, K., Botchan, M. and Cozzarelli, N.R. (1986) Induction of specific transcription by RNA polymerase III in transformed cells. *Mol. Cell. Biol.*, **6**, 3068–3076.
- Singh, K., Carey, M., Saragosti, S. and Botchan, M. (1985) Expression of enhanced levels of small RNA polymerase III transcripts encoded by the B2 repeats in simian virus 40-transformed mouse cells. *Nature*, **314**, 553–556.
- Gaynor, R.B., Feldman, L.T. and Berk, A.J. (1985) Transcription of class III genes activated by viral immediate early proteins. *Science*, **230**, 447–450.
- Hoeffler, W.K. and Roeder, R.G. (1985) Enhancement of RNA polymerase III transcription by the E1A gene product of adenovirus. *Cell*, **41**, 955–963.
- Hoeffler, W.K., Kovelman, R. and Roeder, R.G. (1988) Activation of transcription factor IIIc by the adenovirus E1A protein. *Cell*, **53**, 907–920.
- Yoshinaga, S., Dean, N., Han, M. and Berk, A.J. (1986) Adenovirus stimulation of transcription by RNA polymerase III: evidence for an E1A-dependent increase in transcription factor IIIc concentration. *EMBO J.*, **5**, 343–354.
- Kovelman, R. and Roeder, R.G. (1990) Sarkosyl defines three intermediate steps in transcription initiation by RNA polymerase

- III: application to stimulation of transcription by E1A. *Genes Dev.*, **4**, 646–658.
39. Horwitz,G.A., Zhang,K., McBrian,M.A., Grunstein,M., Kurdistani,S.K. and Berk,A.J. (2008) Adenovirus small e1a alters global patterns of histone modification. *Science*, **321**, 1084–1085.
 40. Ferrari,R., Pellegrini,M., Horwitz,G.A., Xie,W., Berk,A.J. and Kurdistani,S.K. (2008) Epigenetic reprogramming by adenovirus e1a. *Science*, **321**, 1086–1088.
 41. Ferrari,R., Gou,D., Jawdekar,G., Johnson,S.A., Nava,M., Su,T., Yousef,A.F., Zemke,N.R., Pellegrini,M., Kurdistani,S.K., *et al.* (2014) Adenovirus small E1A employs the lysine acetylases p300/CBP and tumor suppressor Rb to repress select host genes and promote productive virus infection. *Cell Host Microbe*, **16**, 663–676.
 42. Fuchs,M., Gerber,J., Drapkin,R., Sif,S., Ikura,T., Ogryzko,V., Lane,W.S., Nakatani,Y. and Livingston,D.M. (2001) The p400 complex is an essential E1A transformation target. *Cell*, **106**, 297–307.
 43. Sapountzi,V., Logan,I.R. and Robson,C.N. (2006) Cellular functions of TIP60. *Int. J. Biochem. Cell Biol.*, **38**, 1496–1509.
 44. Calo,E. and Wysocka,J. (2013) Modification of enhancer chromatin: what, how, and why? *Mol. Cell*, **49**, 825–837.
 45. Montell,C., Courtois,G., Eng,C. and Berk,A. (1984) Complete transformation by adenovirus 2 requires both E1A proteins. *Cell*, **36**, 951–961.
 46. Jones,N. and Shenk,T. (1979) An adenovirus type 5 early gene function regulates expression of other early viral genes. *Proc. Nat. Acad. Sci. USA*, **76**, 3665–3669.
 47. Hardy,S., Kitamura,M., Harris-Stansil,T., Dai,Y. and Phipps,M.L. (1997) Construction of adenovirus vectors through cre-lox recombination. *J. Virol.*, **71**, 1842–1849.
 48. Hsu,E., Zemke,N.R. and Berk,A.J. (2021) Promoter-specific changes in initiation, elongation, and homeostasis of histone H3 acetylation during CBP/p300 inhibition. *eLife*, **10**, e63512.
 49. Dobin,A., Davis,C.A., Schlesinger,F., Drenkow,J., Zaleski,C., Jha,S., Batut,P., Chaisson,M. and Gingeras,T.R. (2013) STAR: ultrafast universal RNA-seq aligner. *Bioinformatics*, **29**, 15–21.
 50. Liao,Y., Smyth,G.K. and Shi,W. (2014) featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. *Bioinformatics*, **30**, 923–930.
 51. Love,M.I., Huber,W. and Anders,S. (2014) Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol.*, **15**, 550.
 52. Quinlan,A.R. and Hall,I.M. (2010) BEDTools: a flexible suite of utilities for comparing genomic features. *Bioinformatics*, **26**, 841–842.
 53. Wang,Z. and Roeder,R.G. (1997) Three human RNA polymerase III-specific subunits form a subcomplex with a selective function in specific transcription initiation. *Genes Dev.*, **11**, 1315–1326.
 54. Weser,S., Gruber,C., Hafner,H.M., Teichmann,M., Roeder,R.G., Seifart,K.H. and Meissner,W. (2004) Transcription factor (TF)-like nuclear regulator, the 250-kDa form of homo sapiens TFIIIB", is an essential component of human TFIIIC1 activity. *J. Biol. Chem.*, **279**, 27022–27029.
 55. Ramirez,F., Dundar,F., Diehl,S., Gruning,B.A. and Manke,T. (2014) deepTools: a flexible platform for exploring deep-sequencing data. *Nucleic Acids Res.*, **42**, W187–W191.
 56. Harlow,E., Franza,B.R. and Schley,C. (1985) Monoclonal antibodies specific for adenovirus early region 1A proteins: extensive heterogeneity in early region 1A products. *J. Virol.*, **55**, 533–546.
 57. Bailey,T.L., Johnson,J., Grant,C.E. and Noble,W.S. (2015) The MEME Suite. *Nucleic Acids Res.*, **43**, W39–W49.
 58. Fornes,O., Castro-Mondragon,J.A., Khan,A., van der Lee,R., Zhang,X., Richmond,P.A., Modi,B.P., Corread,S., Gheorghe,M., Baranasic,D., *et al.* (2020) JASPAR 2020: update of the open-access database of transcription factor binding profiles. *Nucleic Acids Res.*, **48**, D87–D92.
 59. Greber,U.F. and Flatt,J.W. (2019) Adenovirus entry: from infection to immunity. *Annu. Rev. Virol.*, **6**, 177–197.
 60. Konkel,M.K., Walker,J.A., Hotard,A.B., Ranck,M.C., Fontenot,C.C., Storer,J., Stewart,C., Marth,G.T., Genomes,C. and Batzer,M.A. (2015) Sequence analysis and characterization of active Human alu subfamilies based on the 1000 genomes pilot project. *Genome Biol. Evol.*, **7**, 2608–2622.
 61. Bennett,E.A., Keller,H., Mills,R.E., Schmidt,S., Moran,J.V., Weichenrieder,O. and Devine,S.E. (2008) Active Alu retrotransposons in the human genome. *Genome Res.*, **18**, 1875–1883.
 62. Oler,A.J., Alla,R.K., Roberts,D.N., Wong,A., Hollenhorst,P.C., Chandler,K.J., Cassidy,P.A., Nelson,C.A., Hagedorn,C.H., Graves,B.J., *et al.* (2010) Human RNA polymerase III transcriptomes and relationships to pol II promoter chromatin and enhancer-binding factors. *Nat. Struct. Mol. Biol.*, **17**, 620–628.
 63. Moqtaderi,Z., Wang,J., Raha,D., White,R.J., Snyder,M., Weng,Z. and Struhl,K. (2010) Genomic binding profiles of functionally distinct RNA polymerase III transcription complexes in human cells. *Nat. Struct. Mol. Biol.*, **17**, 635–640.
 64. McLean,C.Y., Bristor,D., Hiller,M., Clarke,S.L., Schaar,B.T., Lowe,C.B., Wenger,A.M. and Bejerano,G. (2010) GREAT improves functional interpretation of cis-regulatory regions. *Nat. Biotechnol.*, **28**, 495–501.
 65. Ferrari,R., Berk,A.J. and Kurdistani,S.K. (2009) Viral manipulation of the host epigenome for oncogenic transformation. *Nat. Rev. Genet.*, **10**, 290–294.
 66. Zhao,Y., Wang,J., Liang,F., Liu,Y., Wang,Q., Zhang,H., Jiang,M., Zhang,Z., Zhao,W., Bao,Y., *et al.* (2019) NucMap: a database of genome-wide nucleosome positioning map across species. *Nucleic Acids Res.*, **47**, D163–D169.
 67. Wang,J., Zibetti,C., Shang,P., Sripathi,S.R., Zhang,P., Cano,M., Hoang,T., Xia,S., Ji,H., Merbs,S.L., *et al.* (2018) ATAC-Seq analysis reveals a widespread decrease of chromatin accessibility in age-related macular degeneration. *Nat. Commun.*, **9**, 1364.
 68. McLeay,R.C. and Bailey,T.L. (2010) Motif Enrichment Analysis: a unified framework and an evaluation on ChIP data. *BMC Bioinf.*, **11**, 165.
 69. Shaulian,E. and Karin,M. (2002) AP-1 as a regulator of cell life and death. *Nat. Cell Biol.*, **4**, E131–E136.
 70. Zheng,R., Wan,C., Mei,S., Qin,Q., Wu,Q., Sun,H., Chen,C.H., Brown,M., Zhang,X., Meyer,C.A., *et al.* (2019) Cistrome Data Browser: expanded datasets and new tools for gene regulatory analysis. *Nucleic Acids Res.*, **47**, D729–D735.
 71. Kaaij,L.J.T., Mohn,F., van der Weide,R.H., de Wit,E. and Buhler,M. (2019) The ChAHP complex counteracts chromatin looping at CTCF sites that emerged from SINE expansions in mouse. *Cell*, **178**, 1437–1451.
 72. Pocaterra,A., Romani,P. and Dupont,S. (2020) YAP/TAZ functions and their regulation at a glance. *J. Cell Sci.*, **133**, jcs230425.
 73. Zemke,N.R., Gou,D. and Berk,A.J. (2019) Dedifferentiation by adenovirus E1A due to inactivation of Hippo pathway effectors YAP and TAZ. *Genes Dev.*, **33**, 828–843.
 74. Zancanato,F., Battilana,G., Forcato,M., Filippi,L., Azzolin,L., Manfrin,A., Quaranta,E., Di Biagio,D., Sigismondo,G., Guzzardo,V., *et al.* (2018) Transcriptional addiction in cancer cells is mediated by YAP/TAZ through BRD4. *Nat. Med.*, **24**, 1599–1610.
 75. Stein,C., Bardet,A.F., Roma,G., Bergling,S., Clay,I., Ruchti,A., Agarinis,C., Schmelzle,T., Bouwmeester,T., Schubeler,D., *et al.* (2015) YAP1 Exerts its transcriptional control via TEAD-mediated activation of enhancers. *PLoS Genet.*, **11**, e1005465.
 76. Pope,B.D., Ryba,T., Dileep,V., Yue,F., Wu,W., Denas,O., Vera,D.L., Wang,Y., Hansen,R.S., Canfield,T.K., *et al.* (2014) Topologically associating domains are stable units of replication-timing regulation. *Nature*, **515**, 402–405.

77. Lister, R., Pelizzola, M., Dowen, R.H., Hawkins, R.D., Hon, G., Tonti-Filippini, J., Nery, J.R., Lee, L., Ye, Z., Ngo, Q.M., et al. (2009) Human DNA methylomes at base resolution show widespread epigenomic differences. *Nature*, **462**, 315–322.
78. The ENCODE Project Consortium (2012) An integrated encyclopedia of DNA elements in the human genome. *Nature*, **489**, 57–74.
79. Tasdemir, N., Banito, A., Roe, J.S., Alonso-Curbelo, D., Camiolo, M., Tschaharganeh, D.F., Huang, C.H., Aksoy, O., Bolden, J.E., Chen, C.C., et al. (2016) BRD4 Connects enhancer remodeling to senescence immune surveillance. *Cancer Discov.*, **6**, 612–629.
80. Pelka, P., Ablack, J.N., Fonseca, G.J., Yousef, A.F. and Mymryk, J.S. (2008) Intrinsic structural disorder in adenovirus E1A: a viral molecular hub linking multiple diverse processes. *J. Virol.*, **82**, 7252–7263.
81. Avvakumov, N., Kajon, A.E., Hoeben, R.C. and Mymryk, J.S. (2004) Comprehensive sequence analysis of the E1A proteins of human and simian adenoviruses. *Virology*, **329**, 477–492.
82. Mertens, C. and Roeder, R.G. (2008) Different functional modes of p300 in activation of RNA polymerase III transcription from chromatin templates. *Mol. Cell. Biol.*, **28**, 5764–5776.
83. Orioli, A., Pascali, C., Pagano, A., Teichmann, M. and Dieci, G. (2012) RNA polymerase III transcription control elements: themes and variations. *Gene*, **493**, 185–194.
84. Davis, C.A., Hitz, B.C., Sloan, C.A., Chan, E.T., Davidson, J.M., Gabdank, I., Hilton, J.A., Jain, K., Baymuradov, U.K., Narayanan, A.K., et al. (2018) The Encyclopedia of DNA elements (ENCODE): data portal update. *Nucleic Acids Res.*, **46**, D794–D801.
85. Gevry, N., Hardy, S., Jacques, P.E., Laflamme, L., Svtelisl, A., Robert, F. and Gaudreau, L. (2009) Histone H2A.Z is essential for estrogen receptor signaling. *Genes Dev.*, **23**, 1522–1533.
86. Tucker, J.M. and Glaunsinger, B.A. (2017) Host noncoding retrotransposons induced by DNA viruses: a SINE of infection? *J. Virol.*, **91**, e00982–e00917.
87. King, C.R., Zhang, A., Tessier, T.M., Gameiro, S.F. and Mymryk, J.S. (2018) Hacking the cell: network intrusion and exploitation by Adenovirus E1A. *mBio*, **9**, e00390–18.
88. Ferrari, R., Su, T., Li, B., Bonora, G., Oberai, A., Chan, Y., Sasidharan, R., Berk, A.J., Pellegrini, M. and Kurdistani, S.K. (2012) Reorganization of the host epigenome by a viral oncogene. *Genome Res.*, **22**, 1212–1221.
89. Liu, X. and Marmorstein, R. (2007) Structure of the retinoblastoma protein bound to adenovirus E1A reveals the molecular basis for viral oncoprotein inactivation of a tumor suppressor. *Genes Dev.*, **21**, 2711–2716.
90. Lynch, K.L., Gooding, L.R., Garnett-Benson, C., Ornelles, D.A. and Avgousti, D.C. (2019) Epigenetics and the dynamics of chromatin during adenovirus infections. *FEBS Lett.*, **593**, 3551–3570.
91. Frisch, S.M. and Mymryk, J.S. (2002) Adenovirus-5 E1A: paradox and paradigm. *Nat. Rev. Mol. Cell Biol.*, **3**, 441–452.
92. Tworokowski, K.A., Chakraborty, A.A., Samuelson, A.V., Seger, Y.R., Narita, M., Hannon, G.J., Lowe, S.W. and Tansey, W.P. (2008) Adenovirus E1A targets p400 to induce the cellular oncoprotein Myc. *Proc. Nat. Acad. Sci. U.S.A.*, **105**, 6103–6108.
93. Buchel, G., Carstensen, A., Mak, K.Y., Roeschert, J., Leen, E., Sumara, O., Hofstetter, J., Herold, S., Kalb, J., Baluapuri, A., et al. (2017) Association with Aurora-A controls N-MYC-dependent promoter escape and pause release of RNA polymerase II during the cell cycle. *Cell Rep.*, **21**, 3483–3497.
94. Kenneth, N.S., Ramsbottom, B.A., Gomez-Roman, N., Marshall, L., Cole, P.A. and White, R.J. (2007) TRRAP and GCN5 are used by c-Myc to activate RNA polymerase III transcription. *Proc. Nat. Acad. Sci. U.S.A.*, **104**, 14917–14922.
95. Walz, S., Lorenzin, F., Morton, J., Wiese, K.E., von Eyss, B., Herold, S., Rycak, L., Dumay-Odelot, H., Karim, S., Bartkuhn, M., et al. (2014) Activation and repression by oncogenic MYC shape tumour-specific gene expression profiles. *Nature*, **511**, 483–487.
96. Deleu, L., Shellard, S., Alevizopoulos, K., Amati, B. and Land, H. (2001) Recruitment of TRRAP required for oncogenic transformation by E1A. *Oncogene*, **20**, 8270–8275.
97. Pradhan, S.K., Su, T., Yen, L., Jacquet, K., Huang, C., Cote, J., Kurdistani, S.K. and Carey, M.F. (2016) EP400 Deposits H3.3 into promoters and enhancers during gene activation. *Mol. Cell*, **61**, 27–38.
98. Policarpi, C., Crepaldi, L., Brookes, E., Nitaraska, J., French, S.M., Coatti, A. and Riccio, A. (2017) Enhancer SINEs link pol III to pol II transcription in neurons. *Cell Rep.*, **21**, 2879–2894.
99. Sasaki, T., Nishihara, H., Hirakawa, M., Fujimura, K., Tanaka, M., Kubo, N., Kimura-Yoshida, C., Matsuo, I., Sumiyama, K., Saitou, N., et al. (2008) Possible involvement of SINEs in mammalian-specific brain formation. *Proc. Nat. Acad. Sci. U.S.A.*, **105**, 4220–4225.
100. Creighton, M.P., Cheng, A.W., Welstead, G.G., Kooistra, T., Carey, B.W., Steine, E.J., Hanna, J., Lodato, M.A., Frampton, G.M., Sharp, P.A., et al. (2010) Histone H3K27ac separates active from poised enhancers and predicts developmental state. *Proc. Nat. Acad. Sci. U.S.A.*, **107**, 21931–21936.
101. Mink, S., Haenig, B. and Klempner, K.H. (1997) Interaction and functional collaboration of p300 and C/EBPbeta. *Mol. Cell. Biol.*, **17**, 6609–6617.
102. Bannister, A.J., Oehler, T., Wilhelm, D., Angel, P. and Kouzarides, T. (1995) Stimulation of c-jun activity by CBP: c-jun residues Ser63/73 are required for CBP induced stimulation in vivo and CBP binding in vitro. *Oncogene*, **11**, 2509–2514.
103. Bannister, A.J., Brown, H.J., Sutherland, J.A. and Kouzarides, T. (1994) Phosphorylation of the c-fos and c-jun HOB1 motif stimulates its activation capacity. *Nucleic Acids Res.*, **22**, 5173–5176.
104. Zanconato, F., Forcato, M., Battilana, G., Azzolin, L., Quaranta, E., Bodega, B., Rosato, A., Bicciato, S., Cordenonsi, M. and Piccolo, S. (2015) Genome-wide association between YAP/TAZ/TEAD and AP-1 at enhancers drives oncogenic growth. *Nat. Cell Biol.*, **17**, 1218–1227.
105. Ramji, D.P. and Foka, P. (2002) CCAAT/enhancer-binding proteins: structure, function and regulation. *Biochem. J.*, **365**, 561–575.
106. Di Pascale, F., Nama, S., Muhuri, M., Quah, S., Ismail, H.M., Chan, X.H.D., Sundaram, G.M., Ramalingam, R., Burke, B. and Sampath, P. (2018) C/EBPbeta mediates RNA polymerase III-driven transcription of oncomiR-138 in malignant gliomas. *Nucleic Acids Res.*, **46**, 336–349.
107. Hou, T.Y. and Kraus, W.L. (2020) Spirits in the material world: enhancer RNAs in transcriptional regulation. *Trends Biochem. Sci.*, **46**, 138–153.
108. Liang, L., Cao, C., Ji, L., Cai, Z., Wang, D., Ye, R., Chen, J., Yu, X., Zhou, J., Bai, Z., et al. (2023) Complementary Alu sequences mediate enhancer-promoter selectivity. *Nature*, **619**, 868–875.
109. Cantarella, S., Carnevali, D., Morselli, M., Conti, A., Pellegrini, M., Montanini, B. and Dieci, G. (2019) Alu RNA modulates the expression of cell cycle genes in Human fibroblasts. *Int. J. Mol. Sci.*, **20**, 3315.
110. Di Ruocco, F., Basso, V., Rivoire, M., Mehlen, P., Ambati, J., De Falco, S. and Tarallo, V. (2018) Alu RNA accumulation induces epithelial-to-mesenchymal transition by modulating miR-566 and is associated with cancer progression. *Oncogene*, **37**, 627–637.
111. Larminie, C.G., Cairns, C.A., Mital, R., Martin, K., Kouzarides, T., Jackson, S.P. and White, R.J. (1997) Mechanistic analysis of RNA polymerase III regulation by the retinoblastoma protein. *EMBO J.*, **16**, 2061–2071.
112. White, R.J. (2004) RNA polymerase III transcription and cancer. *Oncogene*, **23**, 3208–3216.
113. Orioli, A. (2017) tRNA biology in the omics era: stress signalling dynamics and cancer progression. *Bioessays*, **39**, 1600158.
114. Gjidoda, A. and Henry, R.W. (2013) RNA polymerase III repression by the retinoblastoma tumor suppressor protein. *Biochim. Biophys. Acta*, **1829**, 385–392.

115. Hirsch, H.A., Jawdekar, G.W., Lee, K.A., Gu, L. and Henry, R.W. (2004) Distinct mechanisms for repression of RNA polymerase III transcription by the retinoblastoma tumor suppressor protein. *Mol. Cell. Biol.*, **24**, 5989–5999.
116. Roman, A.C., Gonzalez-Rico, F.J., Molto, E., Hernando, H., Neto, A., Vicente-Garcia, C., Ballestar, E., Gomez-Skarmeta, J.L., Vavrova-Anderson, J., White, R.J., *et al.* (2011) Dioxin receptor and SLUG transcription factors regulate the insulator activity of B1 SINE retrotransposons via an RNA polymerase switch. *Genome Res.*, **21**, 422–432.
117. Petrie, J.L., Swan, C., Ingram, R.M., Frame, F.M., Collins, A.T., Dumay-Odelot, H., Teichmann, M., Maitland, N.J. and White, R.J. (2019) Effects on prostate cancer cells of targeting RNA polymerase III. *Nucleic Acids Res.*, **47**, 3937–3956.
118. Xie, W., Ling, T., Zhou, Y., Feng, W., Zhu, Q., Stunnenberg, H.G., Grummt, I. and Tao, W. (2012) The chromatin remodeling complex NuRD establishes the poised state of rRNA genes characterized by bivalent histone modifications and altered nucleosome positions. *Proc. Nat. Acad. Sci. U.S.A.*, **109**, 8161–8166.
119. Freese, N.H., Norris, D.C. and Loraine, A.E. (2016) Integrated genome browser: visual analytics platform for genomics. *Bioinformatics*, **32**, 2089–2095.
120. Shin, H., Liu, T., Manrai, A.K. and Liu, X.S. (2009) CEAS: cis-regulatory element annotation system. *Bioinformatics*, **25**, 2605–2606.